Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2012

THREE DIMENSIONAL IN VITRO MODEL OF HEAD AND NECK
SQUAMOUS CELL CARCINOMA
Anna Bulysheva
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Biomedical Engineering and Bioengineering Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/396

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

School of Engineering
Virginia Commonwealth University
This is to certify that the thesis prepared by Anna Alexandra Bulysheva entitled THREE
DIMENSIONAL IN VITRO MODEL OF HEAD AND NECK SQUAMOUS CELL
CARCINOMA has been approved by her committee as satisfactory completion of the
dissertation requirement for the degree of Doctor of Philosophy
W. Andrew Yeudall, School of Dentistry

Gary L. Bowlin, School of Engineering

Hu Yang, School of Engineering

Rebecca L. Heise, School of Engineering

Zendra E. Zehner, Massey Cancer Center

Elena Black, School of Dentistry

Gerald E. Miller, Chair of Biomedical Engineering, School of Engineering

Rosalyn S Hobson, Associate Dean of Graduate Affairs, School of Engineering

J. Charles Jennett, Dean of the School of Engineering

Dr. F. Douglas Boudinot, Dean of the Graduate School
______________________________________(Date)

© Anna Alexandra Bulysheva, 2012
All Rights Reserved

THREE DIMENSIONAL IN VITRO MODEL OF HEAD AND NECK SQUAMOUS CELL
CARCINOMA
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
at Virginia Commonwealth University.
by
ANNA ALEXANDRA BULYSHEVA
B.S. Biology, University of North Carolina at Chapel Hill, 2006
M.S. Biomedical Engineering, Virginia Commonwealth University, 2009

Director: W. ANDREW YEUDALL
ASSOCIATE PROFESSOR, VCU PHILIPS INSTITUTE OF
ORAL AND CRANIOFACIAL MOLECULAR BIOLOGY

Director: GARY L. BOWLIN
PROFESSOR, BIOMEDICAL ENGINEERING

!

Virginia Commonwealth University
Richmond, Virginia
May, 2012

!

"! !

!

!

!

Acknowledgements

I would like to thank the many people who have helped me advance through this
learning process. The support and advice from my advisor and committe, family, labmates and friends have shaped the researcher that I am today.
I would like to thank my advisor, Dr. Andrew Yeudall for taking a chance on a
BME student, and allowing me the freedom to play to my content in the name of science,
while simultaneously guiding me towards becoming a better scientist. Your mentoring,
support and instruction have made this work possible.
My journey through graduate school would not be what it is today, without Dr.
Gary Bowlin. I thank you for your polymer processing equipment and providing the
grounding and motivating scientific guidance.
To Dr. Elena Black, thank you for entertaining my wild ideas and the numerous
scientific discussions as well as traveling many miles to serve on my committee.
I would like to thank each member of my committee Dr. Hu Yang, Dr. Rebecca
Heise and Dr. Zendra Zehner for your guidance and suggestions to improve my research
and dissertation.
!

##!

!

!

!

To Mom and Dad, thank you for your love, blind faith in my abilities and infinite
support. You have made possible opportunities that very few experience in life, and I am
eternally grateful. A special thanks to Michael, for inspiring me to chase that unicorn,
even when it is most elusive.
Finally, my lab-mates and friends: thank you for providing support, in a way of
kind words or actual technical advice. I especially would like to thank Chris Holden,
Huixin Wang, Quan Yuan, Koyal Garg, Yas Maghdouri and Stella Petrova for the many
stimulating and insightful discussions that have brought joy and laughter during the good
and better grad-school days.!

!

###!

!

Table of Contents
Page

Acknowledgements!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!##!
Table of Contents!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!#$!
List of Figures!""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!$##!
List of Tables!""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!%!
List of Abbreviations!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!%#!
Abstract!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!%$!
Chapter 1: Modeling Head and Neck Squamous Cell Carcinoma!"""""""""""""""""""""""""""""""""""""""!&!
HEAD AND NECK SQUAMOUS CELL CARCINOMA!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!&!
MODELS OF HNSCC!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!'!
CELL SOURCES FOR IN VITRO MODELS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!&(!
EXTRACELLULAR MATRIX OF HNSCC!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!&)!
ELECTROSPINNING!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!*+!
SILK FIBROIN!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!*,!
BIOMATERIAL MECHANICAL PROPERTIES!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!*)!
DRUG SENSITIVITY!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!*-!
TAXOL!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!(+!
ANGIOGENESIS IN HNSCC!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!((!
!

#$!

!

!

!

Chapter 2: Hypothesis and Specific Aims!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!'(!
HYPOTHESIS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!('!
SPECIFIC AIMS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!('!
Chapter 3: Materials and Methods!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!')!
SCAFFOLD FABRICATION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!(-!
CELL CULTURE!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!"+!
SCANNING ELECTRON MICROSCOPY!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!"*!
MECHANICAL TESTING!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!"(!
POROSITY!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!""!
RNA EXTRACTION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!""!
WESTERN BLOT!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!",!
FLUORESCENCE MICROSCOPY!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!")!
LIVE/DEAD ANALYSIS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!")!
IMMUNOFLUORESCENT STAINING!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!".!
DRUG DOSE RESPONSE STUDY!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!".!
ELISA for CXCL5 and VEGF-A:!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!"-!
DECELLULARIZATION OF TUMOR ECM!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!,+!
CONDITIONED MEDIUM EXPERIMENTS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!,&!
STATISTICAL ANALYSIS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!,&!
Chapter 4: Cryogenic Electrospun Silk for Mucosal Modeling!"""""""""""""""""""""""""""""""""""""""""!*'!
INTRODUCTION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!,(!
RESULTS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!,,!
!

$!

!

!

!

DISCUSSION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!'.!
Chapter 5: Comparison of Cryogenic Electrospun and In Vivo Models!""""""""""""""""""""""""""!+'!
INTRODUCTION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!)(!
RESULTS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!)"!
DISCUSSION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!.(!
Chapter 6: Anticancer Drug Activity in 3D Culture Model!""""""""""""""""""""""""""""""""""""""""""""""""!,(!
INTRODUCTION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!.'!
RESULTS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!.)!
DISCUSSION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!-"!
Chapter 7: Angiogenic Factors in the 3D HNSCC Model!"""""""""""""""""""""""""""""""""""""""""""""""""""!)(!
INTRODUCTION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!-'!
RESULTS!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!-)!
DISCUSSION!%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%!&+,!
Chapter 8: Discussion!"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!&-+!

Literature Cited!""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!&&)!
APPENDIX A: Conventional Organotypic 3D Model!"""""""""""""""""""""""""""""""""""""""""""""""""""""""!&.-!
APPENDIX B: Negative Controls for Immunofluorescent Staining!""""""""""""""""""""""""""""""!&./!
APPENDIX C: Gene Expression Testing in Cryogenic Electrospun Silk Scaffolds!"""!&.)!
APPENDIX D: One-Way Analysis of Variance!""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!&*/!
APPENDIX E: HN12 Tumor Histology!""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!&*+!

VITA!""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""!&*,!
!

$#!

!

!

!

List of Figures
!

!

/012!

Figure 1.1: Increased incidence of publications using nude mice as an animal model indexed on
PubMed ............................................................................................................................................. 8
Figure 1.2: Organotypic culture system illustration ................................................................. 12
Figure 1.3: Process of electrospinning ..................................................................................... 23
Figure 1.4: Process of cryogenic electrospinning .................................................................... 24
Figure 1.5: Chemical structure of Taxol .................................................................................. 32
Figure 4.1: SEM of cryogenic electrospun silk ........................................................................ 57
Figure 4.2: BJ-hTERT fibroblasts on cryogenic and conventional electrospun scaffolds. ...... 58
Figure 4.3: HN12/mCherry and BJ-hTERT/YFP co-culture on cryogenic and conventional
electrospun scaffolds....................................................................................................................... 60
Figure 4.4: NOKSI/mCherry and BJ-hTERT/YFP co-culture on cryogenic and conventional
electrospun scaffolds....................................................................................................................... 62
Figure 4.5: Immunofluorescent staining of BJ-hTERT and NOKSI for keratin, Ki67 and
involucrin expression on cryogenic and conventional electrospun scaffolds. ................................ 63

!

$##!

!

!

!

Figure 4.6: Immunofluorescent staining of BJ-hTERT and HFK-398 for keratin, Ki67 and
involucrin expression on cryogenic and conventional electrospun scaffolds ................................. 64
Figure 4.7: Viability of cells on electrospun silk scaffolds after 21 days of culture ................ 67
Figure 5.1: SEM of HN12 tumor ECM and cryogenic electrospun silk scaffolds................... 77
Figure 5.2: Immunofluorescent staining of tumor models for Ki67 expression ...................... 78
Figure 5.3: Immunofluorescent staining of tumor models for involucrin expression .............. 79
Figure 5.4: Immunofluorescent staining of tumor models for pan keratin expression ............ 80
Figure 5.5: Immunofluorescent staining of tumor models for vimentin expression ................ 81
Figure 5.6: 3445678957:2;<26=!;=0#6#61!78!=547:!47>29;!87:!?@AB!2CD:2;;#76 .............. 82
Figure 6.1: HN12 cells are sensitive to Taxol in 2D culture .................................................... 89
Figure 6.2: E#$2FG20>!0609H;#;!78!*G!06>!(G!IJ&*!<59=5:2;!78!IJ&*!<299;! ...................... 90
Figure 6.3: HN12 cell survival after 72-hour treatment with 40nM Taxol .............................. 91
Figure 6.4: 3D cultured HN12 cells are Taxol resistant ........................................................... 92
Figure 6.5: K0C79!=:20=2>!IJ&*!<299;!:2=0#6!D:79#82:0=#$2!<0D0<#=H!#6!(G!<59=5:2 .............. 93
Figure 7.1: 3D tumor model co-culture with endothelial cells .............................................. 100
Figure 7.2: HN12 cells express CXCL5 in 3D culture .......................................................... 101
!

$###!

!

!

!

Figure 7.3: TIME-conditioned EBM-2 inhibits CXCL5 expression...................................... 102
Figure 7.4: HN12 cells express VEGF-A in 3D culture ........................................................ 103
Figure 7.5: TIME-conditioned EBM-2 inhibits VEGF-A expression.................................... 104
Figure A-1: Immunofluorescent staining of the conventional organotypic model of HNSCC for
Ki67, pan keratin, vimentin, involucrin and EGFR ............................................................... 141
Figure B-1: Immunofluorescent staining of NIH-3T3 cells grown in 2D for Ki67, pan keratin,
vimentin, involucrin and EGFR ............................................................................................. 144
Figure B-2: Negative controls for immunofluorescent staining of HN12 tumors ................. 145
Figure B-3: Negative controls for immunofluorescent staining of HN12 cells in 2D ........... 146
Figure B-4: Negative controls for immunofluorescent staining of the 3D HN12+BJ-hTERT
tumor model ........................................................................................................................... 147
Figure B-5: Negative controls for immunofluorescent staining of the 3D HN12 tumor model
................................................................................................................................................ 148
Figure C-1: EPS8 and Actin expression is detected by western blot analysis of cryogenic
electrospun silk scaffolds seeded with HN12 cells ................................................................ 151
Figure E-1: H&E staining of HN12 tumors ........................................................................... 157

!

#C!

!

!

!

List of Tables
Page
Table1. 1 Chemotherapy efficacy in HNSCC, phase II clinical trials6. .............................................. 5
Table1. 2 Changes in extracellular matrix composition in HNSCC44. ............................................. 18
Table1. 3 Integrins employed in cell adhesion to silk fibroin substrates. ......................................... 26
Table D- 1 One-way ANOVA results for CXCL5 ELISA results for Figure 7.2 .......................... 153
Table D- 2 Tukey’s HSD test for significant differences in CXCL5 ELISA results for Figure 7.2
........................................................................................................................................................ 154
Table D- 3 One-way ANOVA results for VEGF-A ELISA results for Figure 7.4 ........................ 155
Table D- 4 Tukey’s HSD test for significant differences in VEGF-A ELISA results for Figure 7.4
........................................................................................................................................................ 156

!

C!

!

!

!

List of Abbreviations
!
L<MEGE!

!

0<2=H90=2>!97NM>26;#=H!9#D7D:7=2#6!

LJOPL!

!

0609H;#;!78!$0:#06<2!

L/Q!!

!

04476#54!D2:7C7>#;59DR0=2!

S#;M0<:H904#>2!

JTJUM42=RH9262MS#;V0<:H904#>2W!

XQL!

S7$#62!;2:54!09S54#6!

X:>Y!

!

S:747>27CH5:#>#62!

ZL[MGB!

!

<299!0>R2;#76M42>#0=2>!>:51!:2;#;=06<2!

<GJL!

!

<74D92426=0:H!GJL!

ZAY!!

!

<7976H!87:4#61!56#=;!

ZIL/Q!

!

\V(M<R7904#>7MD:7DH9WM>#42=RH904476#7]M&!D:7D062M;598760=2!

<#;D90=#6!

!

<#;M>#044#62>#<R97:7D90=#654!V33W!

Z[AGL!

!

,M<R97:742=RH98957:2;<2#6!>#0<2=0=2!

*G! !

!

=N7M>#426;#7609!

(G! !

!

=R:22M>#426;#7609!

GL/3!

!

"UT!'M>#04#>#67M*MDR26H9#6>792!

>>I*+!

!

>75S92!>#;=#992>!N0=2:!

G[?[!

!

G59S2<<7U;!47>#8#<0=#76!78!?0192U;!42>#54!

G[QO!

!

>#42=RH9!;5987C#>2!

GJL!

!

>27CH:#S765<92#<!0<#>!

GJ0;2!

!

>27CH:#S765<920;2!

!

C#!

!

!

!

G/XQ!

!

G59S2<<7^;!DR7;DR0=2!S5882:2>!;09#62!

?X[M*!

!

26>7=R29#09!S0;09!42>#54M*!

?Z[!

!

2C=:0<299590:!40=:#C!

?GKL!

!

2=RH9262!>#04#62!=2=:0!0<2=#<!0<#>!

?@A!!

!

2D#>2:409!1:7N=R!80<=7:!

?@AB!

!

2D#>2:409!1:7N=R!80<=7:!:2<2D=7:!

?E3QL!

!

26_H42M9#6`2>!#44567;7:S26=!0;;0H!

?[K!

!

2D#=R29#0!=7!42;26<RH409!=:06;#=#76!

?JLM).!

!

2D#=R29#09M>2:#$2>!625=:7DR#9M0<=#$0=#61!D2D=#>2!

?/Q.!

!

2D#>2:409!1:7N=R!80<=7:!:2<2D=7:!D0=RN0H!;5S;=:0=2!.!

?=X:!

!

2=R#>#54!S:74#>2!

?=RGM&!

!

2=R#>54!R747>#42:M&!

?=OI!

!

2=R0679!

A3KZ!

!

8957:2;<2#6!#;7=R#7<H060=2!

@L/GI!

!

19H<2:09>2RH>2M(MDR7;DR0=2!>2RH>:71260;2!

I*QO"!

!

;5985:#<!0<#>!

IAaM(-.!

!

R5406!87:2;`#6!8#S:7S90;=;!(-.!

IA/!!

!

&T&T&T(T(T(MR2C08957:7M*MD:7D0679!

I?/?Q!

!

JM*MIH>:7CH2=RH9D#D2:0_#62MJUM*M2=R062;59876#<!0<#>!

IJQZZ!

!

R20>!06>!62<`!;b50475;!<299!<0:<#6740!

I/P!

!

!

IB/!

!

R7:;2:0>#;R!D2:7C#>0;2!

RK?BK!

!

R5406!=29742:0;2!:2$2:;2!=:06;<:#D=0;2!!

!

R5406!D0D#99740$#:5;!

C##!

!

!

!

3Z-+!!

!

-+c!40C#409!#6R#S#=7:H!<76<26=:0=#76!

EX! !

!

E5:#0MX2:=06#!

E#X:!

!

!

[2OI!

!

42=R0679!

[[/!

!

40=:#C!42=0997D:7=2#60;2!

JAdX!

!

65<920:!80<=7:M`0DD0X!

JOaQ3!

!

67:409!7:09!`2:0=#67<H=2;!;D76=06275;9H!#447:=09#_2>!

JKZ!

!

!

OG! !

!

7D=#<09!>26;#=H!

/L@?!

!

D79H0<:H904#>2!129!292<=:7DR7:2;#;!!

/XQ!!

!

DR7;DR0=2!S5882:2>!;09#62!

/XQK!

!

/XQMKN226!

/ZB!!

!

D79H42:0;2!<R0#6!:20<=#76!

/?K!!

!

/XQM?GKLMK:#=76!eM&++!

/3! !

!

D:7D#>#54!#7>#>2!

/[QA!

!

DR26H942=RH9;59876H9!8957:#>2!

BJL!

!

:#S765<92#<!0<#>!

BK! !

!

:2$2:;2!=:06;<:#D=#76!

QZZ!!

!

;b50475;!<299!<0:<#6740!

QGQ!!

!

;7>#54!>7>2<H9!;59DR0=2!

QA! !

!

;#9`!8#S:7#6!

;%2%4%!

!

;=06>0:>!2::7:!78!=R2!4206!

Q?[!

!

;<066#61!292<=:76!4#<:7;<7DH!

!

9#=R#54!S:74#>2!

676M=0:12=#61!<76=:79!

C###!

!

!

!

KXQ!!

!

K:#;MS5882:2>!;09#62!

KZE!!

!

=7=09!<299!9H;0=2!

K@AMf!

!

=:06;87:4#61!1:7N=R!80<=7:!f!

K@AMg!

!

=:06;87:4#61!1:7N=R!80<=7:!g!

K3[?!<299;! !

=29742:0;2!#447:=09#_2>!4#<:7$0;<590:!26>7=R29#09!<299;!

K[X!

!

=2=:042=RH9S26_#62!

KKXQ!

!

KN226M*+!#6!!K:#;!S5882:2>!;09#62!

KN226M*+! !

D79H7CH2=RH9262V*+W;7:S#=06!4767905:0=2!

YP! !

!

59=:0$#792=!

P?@AML!

!

$0;<590:!26>7=R29#09!1:7N=R!80<=7:!L!

hA/!!

!

H2997N!8957:2;<26=!D:7=2#6!

!

C#$!

!

!

!

Abstract

THREE DIMENSIONAL IN VITRO MODEL OF HEAD AND NECK SQUAMOUS
CELL CARCINOMA

By Anna A. Bulysheva, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2012

Major Director: W. Andrew Yeudall
ASSOCIATE PROFESSOR, VCU PHILIPS INSTITUTE OF
ORAL AND CRANIOFACIAL MOLECULAR BIOLOGY

!

C$!

!

!

!

Head and neck squamous cell carcinomas (HNSCC) are among the leading causes
of cancer related deaths throughout the world. The survival rate for this type of cancer is
extremely low and has not changed significantly in recent decades. There is an imperative
need to study tumor progression in a representative model in order to generate more
knowledge about this disease as well as develop more effective treatment options. Multiple
methods already exist for studying HNSCC and other types of cancers, including in vitro
and in vivo models. Although in vivo models are more representative of the human
carcinomas in terms of complexity of the microenvironment the tumor cells experience,
they are difficult to manipulate and many experiments cannot be performed easily in whole
organisms; therefore, in vitro models are used. Current in vitro models are typically twodimensional (2D) monolayer cultures that are easily manipulated for a controlled
environment, but these fail to mimic the native microenvironment in terms of threedimensional (3D) interactions present in vivo. The literature documents that several 3D
organotypic models of HNSCC have been created, showing significant differences in
tumor response to drugs between these models and traditional 2D culture systems, perhaps
suggesting a closer representation of human HNSCC. However, these models were not
rigorously validated, with little comparison to in vivo tumor behavior.
We developed a 3D HNSCC in vitro model using electrospun scaffolds to mimic
the extracellular matrix as well as using a HNSCC-derived tumor cell line, HN12, in co!

C$#!

!

!

!

culture with a supporting fibroblast cell line. We compared the model to the same tumor
cell line grown in vivo in immunodeficient mice. We also investigated drug sensitivity of
tumor cells in our model compared to conventional monocultures to determine whether
differences exist. Finally, we investigated pro-angiogenic properties of tumor cells in this
model. The long-term goal is to develop a model that can be manipulated easily to study
tumorigenic mechanisms and potential treatments.
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Chapter 1: Modeling Head and Neck Squamous Cell Carcinoma

HEAD AND NECK SQUAMOUS CELL CARCINOMA
!

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common
malignancy in the world, with primary lesions becoming locally aggressive and often
metastasizing, principally to regional lymph nodes. The five-year survival rate for patients
with HNSCC is extremely low, on the order of 50% 1 . HNSCC encompasses epithelial
malignancies in the paranasal sinuses, nasal cavity, oral cavity, pharynx and larynx 1, 2 .
Approximately 35,000 people in the U.S. will develop HNSCC in 2012, with
approximately 6,800 people dying from the disease 3 . Men are more than twice as likely to
develop oral cancer than women, which is correlated with higher incidence of alcohol and
tobacco product consumption by men than women 3 .
Several risk factors exist for developing HNSCC. There are strong correlations
between tobacco and alcohol exposure and HNSCC carcinogenesis. Human papillomavirus
(HPV) has also been correlated with development of HNSCCs 1, 2 with a number of nondrinkers and non-smokers still developing the disease

4, 5

. It has been determined that

many of oral cancers test positive for HPV DNA, indicating HPV infection 3 . HPV is
!

&!

!

!

!

thought to be the likely cause of oral cancer in non-smokers who drink little to no alcohol
with primarily HPV-16 causing cancer 6 . People with genetic diseases such as Fanconi
anemia or dyskeratosis congenital are at a high risk of developing cancer, including cancer
of the mouth and throat 3 . Two-thirds of patients diagnosed with HNSCC present with
advanced stage disease 2 . Patients diagnosed with recurrent or metastatic HNSCC have a
median survival of approximately 1 year 6 . The progression of disease follows the pattern
of exposure to carcinogen, hyperplasia, mild dysplasia, severe dysplasia and ultimately
invasive (and sometimes metastatic) carcinoma, with metastasis to the adjacent and
cervical lymph nodes prior to spreading to more distant sites, such as liver and lung 2, 7 .
The standard treatment for HNSCC is surgery and radiotherapy. Improvements in
surgical and radiotherapy techniques have resulted in improved survival rates, however the
recurrence rates are still high requiring other forms of treatments. Chemotherapy has
become a more frequently used form of treatment in the recent years in conjunction with
surgery and radiotherapy. Targeted therapy is also becoming more common, with limited
applications 1, 3, 5 .
Surgery is the primary and most commonly used form of oral cancer treatments. It
is used for early stages of the disease and localized tumors. The goal is to remove the
entire tumor with enough of a margin to prevent recurrence. Possible risks and side effects
from surgery include blood clots, infection, complications from anesthesia, pneumonia,
chronic pain, problems eating and speaking. Surgery can be disfiguring, particularly with
!
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larger tumor volume, or harder to access areas, with possible removal of bones in the face
or jaw requiring reconstructive surgery and possible bone and skin grafts to restore some
vital function, such as speech and swallowing 3 . The benefit of surgery is the possibility to
remove the entire tumor if cancer is localized and diagnosed early 1, 5 . Advanced stages of
the disease often require treatment of non-resectable tumors, thus requiring non-invasive
treatments such as radiotherapy, chemotherapy and targeted therapy.
Radiotherapy is often used to treat small tumors or in conjunction with surgery or
chemotherapy. It is also used in order to shrink larger tumors prior to surgery or for
tumors in sensitive areas where surgery is not possible. The benefit of radiation therapy is
the ability to treat tumors with minimal invasiveness to the surrounding tissue. Side effects
include skin tone change, hoarseness, loss of sense of taste, development of sores in mouth
or throat, difficulty eating and drinking, permanent damage to salivary glands, damage to
the jaw bone, damage to the pituitary or thyroid gland or combinations of the above 3 .
Chemotherapy has evolved from palliative care to standard curative care, with
variable success 2 . The chemotherapy is usually used in combination with surgery and
radiotherapy to reduce non-resectable tumor load 5 . Drugs frequently used for treatments
of oral cancer individually or in combination are cisplatin, 5-fluorouracil (5-FU),
carboplatin, paclitaxel (Taxol®), docetaxel (Taxotere®), methotrexate, ifosfamide (Ifos®),
and bleomycin 3 . Benefits of chemotherapy include a non-invasive treatment with mostly
temporary side effects suffered during treatment. The common side effects are hair loss,
!

(!

!

!

!

mouth sores, loss of appetite, nausea and vomiting, diarrhea, low white blood cell counts,
low platelet counts, low red blood cell counts, and possible neuropathy 3 . Chemotherapy
is often administered in combination of two drugs or a drug and radiotherapy. Cisplatin is
the most commonly used drug in either combination with 5-FU or radiotherapy 3 . Table
1.1 summarizes the commonly used chemotherapy treatments and their efficacy.
The only routinely, clinically used targeted therapy for HNSCC is cetuximab, a
monoclonal antibody therapy against the epidermal growth factor receptor (EGFR), which
is expressed in many HNSCC and is often overexpressed in HNSCC metastasis 3, 6 . There
is a statistically significant increase in overall survival of patients treated with
chemotherapy and cetuximab up to 10 months survival and 36% response 6, 8 , however the
significance of quality of life improvement is minimal. There are significant side effects
associated with using monoclonal antibodies. These include acneiform skin rash,
hypomagnesemia, and a risk of anaphylactic reaction 6, 8 .
The low survival rates for recurrent or metastatic HNSCC indicate the need for
more effective treatments, making tumor development and progression an active area of
research. Since studying human disease in humans is not possible for a multitude of
reasons, we must rely on models to obtain critical information about the disease to advance
better treatments. The information gained from the models is only relevant if the models
are representative of the disease, therefore developing and validating optimal models of
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human HNSCC is critical for understanding disease progression and improving the quality
of life of affected patients 1 .

Chemotherapeutic

Response Rates (%)

Median survival (months)

Pemetrexed

26

7.3

Docetaxel

20-42

6.7

Paclitaxel

36-40

9.2

Gemcitabine

0-13

6

Ifosfamide

4-42

4-11

Capecitabine

24

7.3

Irinotecan

14

N/A

Vinorelbine

6-16

5-8

Ixabepilone

16

7.2

Cisplatin

17

5.7

5-fluoruracil

13

5.7

Methotrexate

10

5.6

Carboplatin, 5-fluoraracil

21

5.0

Cisplatin, 5-fluoruracil

32

6.6

Cisplatin, paclitaxel

32

6.6
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MODELS OF HNSCC
!

In vitro study of healthy and diseased animal tissues started with Harrison in 1907
with his first report of tissue culture of frog nerves 9 . Unfortunately propagation of animal
tissues in vitro was only possible with the cells that migrated out or grew out of the tissue
samples, while the remainder of the tissue fragment could not be maintained in its viable
state 10 . Disaggregation of individual cells from tissues and subsequent culture of those
cells came a couple of years later with culture of mouse L-cells 10 . For the next hundred
years the field has predominantly focused on culture of individual cells with the addition of
trypsin to the tissue culture methodology in 1916 for freeing cells of their matrix and with
the subsequent establishment and propagation of the first human cell line, the HeLa cell
line, in 1952 10, 11 . The HeLa cell line was not only the first human cell line, but also the
first human cancer cell line, establishing the first 2D cell culture model of human cancer 10,
11

. To this day, the most extensively used tumor model system (including the HNSCC

model system) is the two-dimensional (2D) monolayer culture of human tumor-derived
cell lines 12-15 . Although a large body of knowledge has been generated from studying
such models, studies have shown that 2D culture falls short of mimicking the 3D
interactions that most cells in the body experience in their native microenvironment 1, 16 .
Cancer animal studies predate human cancer cell line cultures with animal cancer
transplantation studies dating back to 1907 with the first conference of the American
!
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!

Association of Cancer Research 17 . A significant animal model tool, the nude mouse, was
discovered in 1962 by Grist and later described by Flanagan in 1966

18

.

Flanagan

described these mice to be “nude”, which was distinct from hairless, since they did develop
hair follicles at birth 18 . These mice were later discovered to lack a thymus and be severely
immunocompromized 19, 20 . They are unable to produce T lymphocytes, resulting in no
antibody formation dependent on helper T cells, no cell mediated immune response, no
delayed-type hypersensitivity response, no destruction of virally infected or malignant
cells, and most importantly no allograft or xenograft rejection 20 . Due to their inability to
reject allo- or xenotranspants, nude mice have been routinely used as an in vivo model for
immunological, dermatological, cosmetic, oncological and transplantation studies 20 . The
first report of growing xenografted human tumor in nude mice in 1969 21 , was followed by
numerous cancer research studies using nude mice as the model organism 22 . This list
includes transplantation of HNSCC cell lines 1, 23 . Figure 1.1 shows the incidence of
studies using nude mice since their discovery. The complete complexity of human disease
is missing in these models due to the lack of a competent immune system, which plays an
important role in spontaneous human tumor development. The advantage of using these
models for human tumor development studies is that these human tumors grow as three
dimensional tissues and interact with an entire organism, therefore many features of human
tumors in vivo are represented in the model such as histopathology, local regional invasion
and metastatic potential 1, 24 .
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Other in vivo models include induced tumor development in syngeneic animals.
These models often fail to behave in the same manner as those spontaneously occurring in
humans 1 . The induced tumors do appear to be similar to their human analogs on the
microscopic level, but bear no resemblance in clinically relevant ways, in terms of tumor
development 1 . The syngeneic animals are often inbred populations lacking the genetic
heterogeneity and complexity of human cancer 1 .
Chemically induced carcinogenesis has been employed for modeling many human
cancers including HNSCC 1, 24 . There are several types of chemically induced models of
HNSCC. Researchers often used carcinogens such as polycyclic hydrocarbon 9,10
dimethyl-1,2 benzanthracene (DMBA) or 4-nitroquinoline 1-oxide (4NQO) or 12-Otetradecanoylphobol-13-acetate, resulting in high frequency of oral cancer in rodent
models

24

. These models allow for studying molecular changes seen in human

tumorigenesis, however it is not possible to isolate the effect of specific genes and their
role in oral carcinogenesis 24 .
Transgenic animals have been widely used to study particular oncogenes and their
relation to HNSCC 24 . Oral carcinoma transgenic models have been frequently achieved
by using the keratin 5 (K5) or keratin 14 (K14) promoters to drive the expression of the
oncogene of interest, such as Akt or K-ras 24 . These models do appear to mimic many
major clinical characteristics of HNSCC, however there are still considerable shortcomings
to these animal models as well. Although the promoters that are driving the expression of
!
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!

!

the genes of interest are constrained to the oral epithelium, the stromal cells of the animal
may also express the transgene, thus it is possible for non-specific tissues to express the
transgene. Also, no single gene drives oral carcinogenesis, therefore the study of single
gene expression does not account for the complexity of human disease 24 .
The most conventional and most frequently used in vitro model of any tissue
system remains the two-dimensional (2D) culture of cell lines on tissue culture plastic!*' .
The advantage of the 2D model is the ease of controlling experimental conditions as well
as the ease of measuring the experimental outcomes. A major disadvantage of using human
cell lines cultured as monolayers is the marked lack of complexity present in the human
body that the tumor cells normally experience, such as 3D interactions with the
extracellular matrix, other tumor cells, host cells and the host immune system. The notable
limitations of these models led to the development of various organotypic culture systems.
The traditional organotypic culture system for HNSCC starts with fibroblasts imbedded in
gels consisting of type I collagen. Then, after the collagen is allowed to polymerize, the
layer of epithelial cells is seeded over the top of the collagen. After the epithelial cells are
allowed to attach, the entire culture system may or may not be raised to the air-liquid
interface! *'M(+ . Figure 1.2 shows the schematic for a traditional organotypic cell culture
system. The determination if raising to air-liquid interface is necessary depends on whether
stratification and differentiation of epithelial cells is necessary for the specific experiments
being undertaken. When modeling tissues that are not normally exposed to air in vivo or
!
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tissues that do not require stratification of the epithelial cell layer, the cultures are usually
kept submerged. Cultures that are modeling epithelium exposed to air, or those requiring
stratification and differentiation of the epithelial cells, are raised to the air-liquid interface
for induction of stratification and differentiation of epithelial cells! *'M(+ . One source of
variability between organotypic models of HNSCC originates from the choice of the
fibroblast cell line and the carcinoma cell line. Fibroblast phenotypes vary from tissue to
tissue, as well as within a given tissue! *-T! (& . Since fibroblasts are added to the culture
system as the stromal component and the fibroblast phenotype can direct tumorigenesis,
including invasion! *-T! (+ , it is important to choose an appropriate fibroblast lineage.
Therefore, many researchers choose to isolate fibroblasts from the same tumor sample as
the tumor cells!*)T!*.T!(+ . The advantage of these models is that some of the complexity of the
native 3D environment is replicated. However, it is difficult to speak towards the fidelity
of these models, since they are rarely rigorously validated as a substitute for the subject
that is otherwise unavailable for study!& . Attempts to validate experimental substitutes as
being representative of the spectrum of natural development and biology seen in specific
human cancers are lacking for these and many other cancer models!& .
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CELL SOURCES FOR IN VITRO MODELS
!

More than 300 human cancer cell lines for modeling HNSCC have been established
since the early 1950s! ) . The cultures are usually established by the explant culture of
surgically harvested tumor tissue!)T!(* . The outgrowing tumor cells are usually propagated
with feeder 3T3 fibroblasts, and are then separated and sub-cultured without the feeder
cells!)T!(* . The advantage of using the feeder cells is the promotion of clonogenic growth of
the tumor cells in vitro through epithelial-mesenchymal interactions. The disadvantage of
using feeder cells is their potential contamination of tumor cell lines. There are many cells
sources for modeling normal, dysplastic, and metastatic oral epithelium. Here we outline
some important cells lines that have been used to model the different stages of HNSCC
progression.
!"#$%
One frequently used model HNSCC cell line, the WSU-HN12 or simply the HN12
cell line was established in Wayne State University in 1994 32 . Tumors were harvested
from a patient with a primary tumor at the base of the tongue, with metastasis in adjacent
lymph nodes. The HN12 cell line was established from the lymph node specimen, while
another cell line, the HN4 cell line was concurrently established from the primary tumor of
the same patient 32 . Over 50 studies indexed on PubMed 25 characterize these cells as
!
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representative cells of HNSCC in a variety of mechanistic as well as drug response studies
12, 33-36

. The majority of the studies on HN12 cell have been conducted in 2D cultures,

with some studies reporting injecting these cells in nude mice for in vivo models. These
carcinoma cells have been shown to be highly proliferative, motile and tumorigenic in
vivo. HN12 cells have reduced expression of keratins 13, 14 and 15 compared to primary
tumor derived HN4 cells. Inhibition of vimentin expression in HN12 cells, results in
reduced proliferation, migration and invasion in vitro, and reduced tumorigenicity in
athymic mice 34 . Studies on HN12 cells indicating the overexpression of vimentin and
reduced expression of K14 and K15, correlated with increased motility, proliferation and
invasion are consistent with the acquisition of mesenchymal characteristics by these cells
during tumorigenesis. Therefore epithelial to mesenchymal transition is possibly involved
in tumor progression 34 . They have also been shown to be resistant to cisplatin 36 .

&'()*+,*%
The advantage of using cell lines as disease models is the ability to study molecular,
biochemical, genetic and immunological properties of HNSCC, with relative ease of
experimental design, sample homogeneity and low cost!) . The disadvantage is the loss of
the 3D complexity of tissue structure and function. Therefore, multiple 3D organotypic
!
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models of HNSCC have been developed!& . A common trait of organotypic models is the
presence of tumor cell lines with supporting cells such as fibroblasts!*)T!*.T!(+ . The majority
of the studies with HNSCC organotypic models employ fibroblasts isolated from the same
region of the same tumor as the cancer cell line origin. The advantage of using the cancer
associated feeder fibroblasts is their strong promotion of cancer cell proliferation!*)T!*.T!(+ .
Due to the high variability in fibroblast phenotype within any given tissue!*-T!(& , as well as
the increasing phenotype changes with increasing passage number of normal sub-cultured
cells!&+ , a more easily standardized cell line is desirable for establishing a model HNSCC
system. In order to minimize effects from variation between fibroblast phenotypes, one
could use a stably immortalized cell line for the stromal component. The BJ fibroblast cell
line, retrovirally immortalized with human telomerase reverse transcriptase, is one such
cell line! () . Immortalized cells, such as this cell line, are more homogenous in their
differentiation states than are primary cells and their subcultures, but these cells are not
likely to carry the many genetic mutations characteristic of cancer cells. They maintain a
stable genotype, and can be propagated for many more passages than their parental cell
line, without notable change to their phenotype!&+T!() .
!-.(/01%
Organotypic models have been used for modeling normal epithelium as well as
transformed epithelium. One cell line commonly used for modeling normally
differentiating epithelium is the human foreskin keratinocyte (HFK) cell line 398. The
!
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HFK-398 cell line was immortalized with hTERT! (. . This cell line has been shown to
undergo normal terminal differentiation in a typical organotypic culture model after
exposure to air-liquid interface!(. . HFK-398 cells have been used to study keratinocyte
differentiation, proliferation and adhesion. These cells are capable of proliferating,
differentiating and stratifying when cultured in organotypic conditions at air-liquid
interface!(. .
"2.34%
Modeling dysplastic oral epithelium has also been an important element of
understanding tumor progression. Cell lines such as D20 and DOK, which were derived
from a lateral tongue dysplasia and dorsal tongue dysplasia respectively, have been used
extensively in in vitro modeling of the oral mucosa!(- . Dysplastic oral epithelial cells have
undergone genetic changes that result in blocked differentiation and increased
proliferation. Dysplastic cells do not invade through the basement membrane and are
therefore distinct from carcinoma cells that are capable of in vivo invasion through the
basement membrane! & .

The normal oral keratinocytes, spontaneously immortalized

(NOKSI) cells, which are a gift from Dr. J.S. Gutkind, (NIDCR, Bethesda, MD), may
potentially be dysplastic cells that are more basal cell like or are less differentiated and are
highly proliferative. Although, there is no known literature reporting on NOKSI cells,
these cells are not expected to differentiate as would normal epithelial cells when exposed
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to the air-liquid interface in an organotypic model, based on their spontaneous
immortalized nature.

EXTRACELLULAR MATRIX OF HNSCC

Extracellular matrix (ECM) has many functions including providing mechanical
and structural support, providing cell anchoring sites, aiding in cell-cell and cell-matrix
communications, directing cell orientation, controlling cell metabolic activity, maintaining
and dictating differentiation, guiding embryonic, fetal and somatic tissue development,
providing provisional wound healing substratum, and selectively inhibiting or promoting
cell migration and proliferation!"+ .
Normal oral epithelium contains layers of ECM composed of collagen, laminin,
fibronectin, and glycosaminoglycans. The epithelial cells grow on the basement
membrane. The basement membrane is primarily composed of collagen IV, lamininentactin complexes, and proteoglycans! "& . The basement membrane proteins mediate
signals through attachment to the cytoskeleton, resulting in modulation of cell adhesion,
cell shape, migration, proliferation and differentiation!"& . The underlying connective tissue
of the dermis is composed of collagen, elastin and reticular fibers, which are bound to the
basement membrane. The primary ECM components of the dermis are fibrous collagens I
and III!"* . Other components include fibronectin, laminins and proteoglycans!"* .
!

&)!

!

!

!

ECM Component

Primary location of ECM
components in normal oral
mucosa

Elevated expression of ECM
components in HNSCC
ECM

Collagen I

Dermis

Transformed keratinocytes,
and differentiated SCC

Collagen III

Dermis

Collagen IV

Basement membrane

Nodal disease

Collagen V

Basement membrane

Tumor cells

Collagen VII

Basement membrane-dermis
interface

Tumor cells

Collagen XI

Basement membrane-dermis
interface

Tumor cells

Collagen XVII

Hemidesmosome

Dysplasia, invasive edge of
SCC

Fibronectin

Basement membrane,
dermis

Tumor cells, stroma

Laminin-5

Hemisdesmosome

Tumor cells

Laminin-6

Basement membrane

Laminin-10/11

Basement membrane
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During carcinogenesis, the ECM is remodeled to allow for invasion of the carcinoma cells
into underlying tissue! "* . Table 1.2 summarizes the documented changes in ECM
composition during carcinogenesis. The composition of oral SCC ECM is well
documented with multiple reports about the molecular changes that occur during
carcinogenesis!"*M"" . Little attention has been dedicated to the morphology of the ECM in
terms of fiber dimension, and orientation. A few studies indicate that the change in ECM
stiffness plays an important role in cell response! &'T! ", . During tumor progression and
switch to a metastatic phenotype, the ECM is not only remodeled in terms of
compositional change, but also in terms of increasing stiffness of the matrix!&'T!(+T!""M"' . It
has been shown that increase in ECM stiffness of SCC tumors is correlated with an
increase in matrix fiber size!"" . Therefore it appears that there might be significance in not
only the composition of the ECM, but also the morphological changes that guide
carcinogenesis, similar to the role of the ECM in embryonic development!"+ .
The importance of the ECM in cell-cell, and cell-matrix interactions, is the reason
numerous studies attempt to mimic the ECM for various regenerative medicine
applications as well as in vitro tissue modeling of disease models!&'T!"+ .
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ELECTROSPINNING
!

Electrospinning is a commonly used tissue engineering technique for creating
biomimetic, extracellular matrix analogues that can be used for 3D in vitro cell culture as
well as for implantable tissue constructs. Electrospinning is accomplished by placing a
polymer solution in a static electric field. The polymer solution can be placed into a
syringe while applying a voltage to the needle tip of that syringe. Figure 1.1 shows a
typical electrospinning process diagram. A grounded collecting target is placed a certain
distance away from the needle tip, creating an electric field, with electrostatic forces
pulling the polymer solution in the direction of the target. Once the electrostatic force is
higher than the surface tension forces at the tip of the needle, long entangled polymer
chains are drawn out and carried toward the collecting target. The solvent evaporates
during this travel of the fibers to the target, leaving dry polymer fibers collecting on the
grounded surface forming a non-woven fibrous scaffold with fibers of the order of 50nm10µm in diameter, depending on a multitude of electrospinning parameters, such as the
polymer type, solution concentration, air gap distance, applied voltage, humidity, and
temperature 47 .
Many natural and synthetic polymers have been electrospun for the purpose of
simulating the cell-matrix interactions seen in vivo. These polymers include collagen I,
collagen II, elastin, fibrinogen, gelatin, chitosan, polydioxanone, polycaprolactone,
!
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polylactic acid, and polyglycolic acid 47 . One natural material that is frequently used for
tissue engineering purposes is silk fibroin, due to its biocompatibility and mechanical
properties 48 , as well as its structural similarities to collagen 49 . Electrospun silk has been
used for various tissue engineering applications including in vitro keratinocyte-fibroblast
co-culture with excellent cell adhesion to the surface of the scaffolds 50 .
One major drawback to the application of electrospun scaffolds is limited cell
infiltration and, therefore, limited three-dimensional cell-cell and cell-matrix interactions,
as well as limited vascular ingrowth potential upon implantation of such constructs due to
restricted void space between fibers 51, 52 . Possible solutions to increasing cell infiltration
into electrospun scaffolds include electrostatically spraying cells into a nascent scaffold
during the electrospinning process 53 . While this method is effective at integrating cells
throughout the entire volume of the scaffold, vascular ingrowth potential remains poor due
to lack of adequate void space for cell migration 51 . Another approach to increase porosity,
and therefore increase cell infiltration, is the inclusion of sacrificial fibers that can be
dissolved after scaffold electrospinning is complete

54, 55

.

However, minimal cell

infiltration has been shown with this method 55 . The cotton-ball electrospinning technique
has also been applied to improve cell infiltration with positive results for one week of in
vitro cell culture

56

. Low-temperature electrospinning, also known as cryogenic

electrospinning, is a promising technique that addresses the issue of increasing void
volume between electrospun fibers and therefore facilitating cell infiltration throughout the
!
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entire volume of the electrospun scaffolds 52, 58, 59 . Figure 1.4 illustrates the process of
cryogenic electrospinning. Cryogenic electrospinning uses ice crystals throughout the
growing scaffold to prevent formation of highly compacted fibers during the
electrospinning process. The ice crystals are then removed by freeze-drying the scaffolds,
leaving large void spaces for cell infiltration. The resulting scaffolds support cell
infiltration in vitro and vascularization in vivo 52, 58 .
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SILK FIBROIN

Bombyx mori silkworm silk has been used in textiles for millennia and medical sutures
for centuries!'* . The combination of the mechanical and biocompatibility properties of silk
protein has been an asset for its use for biomedical applications!".T!'( . Silk has been used
for sutures, but recently it has been suggested for other biomedical applications, such as
ECM mimicking scaffolding for tissue regeneration, wound healing substrata, and as a
drug delivery vehicle! '* . Silk has been processed to form fibrous scaffolds, films,
hydrogels, foams, spheres, and capsules for mimicking ECM!'* . Sonicated silk hydrogels
as well as electrospun silk scaffolds have been used for modeling normal skin!,+T!'" .
There are two major proteins present in the cocoons of the silkworm, sericin and silk
fibroin. Sericin is highly inflammatory when presented in vivo with fibroin, and does not
contribute to the structural properties of the fibrous silk fibroin. Therefore, only silk fibroin
is used for biomedical applications!,,T!', . The fibrous helical structure of silk resembles that
of fibrous collagens in contrast to globular proteins!"- . Although Bombyx mori silkworm
silk fibroin lacks the hallmark RGD sequence for mimicking typical collagen/integrin
binding!'* , various studies show cell adhesion to silk biomaterials via integrin binding.
Table 1.3 summarizes the currently known integrins that have been employed by different
cell types to bind to silk scaffolds.

!
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Integrin

Cell type

Reference

Normal in vivo
integrin ligand!''

!2"1

Human umbilical
vein endothelial
cells,

!')M'-

Collagen I, II, III
and IV, laminin

!'.T!'-

Fibronectin

Osteoblasts,
human mesenchymal
stem cells
!5"1

Osteoblasts,
human mesenchymal
stem cells

!V"1

Human umbilical
vein endothelial
cells

!')

Fibronectin,
vitronectin

!V"3

Rat endothelial cells

!)+

Vitronectin,
fibrinogen, vWF,
fibronectin,
thrombospondin,
osteopontin and
collagen
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Silk fibroin biomaterials have been shown to promote angiogenesis within the
scaffolds when the scaffolds are implanted in vivo in rat animal models!)+T!)& . Other studies
conducted in vitro indicate that silk biomaterials support migration and capillary like
formation by endothelial cells!)* . Silk sutures are used for inducing neovascularization for
modeling angiogenesis in a rabbit cornea!)( . These studies indicate that silk fibroin is an
excellent biomaterial for promotion of angiogenesis!'"T!')T!)+M)( .
Silk fibroin ability to induce cell adhesion via integrin binding, pro-angiogenic
properties, and its biocompatibility together with our preliminary studies showing the
ability of cryogenic electrospun silk to support growth, survival and infiltration of HN12
cells throughout the volume of the scaffolds, makes it of interest to investigate whether
cryogenic electrospun silk can be used to develop a 3D in vitro model of HNSCC.

BIOMATERIAL MECHANICAL PROPERTIES
!

Tissue engineering often aims to mimic native tissues in every possible way, this
includes the mechanical properties of the tissue of interest. There are several mechanical
properties that are important for evaluation of intrinsic characteristics of tissues. The
strength of the material is evaluated by determining the amount of force the material can
withstand per cross-sectional unit area of that material, also known as stress and is
!
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measured in newtons per square meter (N/m2) or pascals (Pa). The peak stress the material
can withstand is therefore usually used to compare biomaterials. Another material property
that is often measured is the deformation of the solid material under known stress, or
strain. Deformation is a unitless measure of the ratio between the initial and the deformed
object shape. In the case of uniaxial longitudinal deformation, the material is stretched
under know stress and the ratio between the change in length to the final length prior to
failure of the material is determined. The relationship between stress and strain of the
material can be described by the tensile or Young’s modulus, which only holds true for
isotropic materials, uniaxially loaded that are assumed to stretch proportionally to the
stress applied, within the material’s elastic or linear range. The modulus is reported in
pascals since strain has no units! )" . Such material properties are often reported for
biomaterials, especially biomaterials intended to perform mechanical functions that normal
tissues usually perform, such as bone, ligament, tendon, skin, and blood vessel replacement
with the intention of matching or improving the function of the engineering tissue relative
to the native!), .
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DRUG SENSITIVITY
!

Several studies have shown that drug sensitivity of tumor cells is reduced when
they are cultured in 3D culture compared to 2D monolayers 40, 76, 77 . There is a notable
discrepancy between the efficacies of chemotherapeutic drugs applied to 2D culture of
cancer cells and in vivo application of these drugs to the same cancers 78 , raising the
possibility of a protective effect that exists in vivo that is missing in 2D culture systems.
The clinical response to chemotherapeutic drugs is very low, with the highest reported
response rate of 42%

6

. Differences in gene expression, cell-matrix and cell-cell

interactions are hypothesized to account for the variability in drug response between
current models and actual human disease. In particular specific integrin binding of the
tumor cells to the ECM may promote pro-survival mechanisms that are not present in 2D
culture 79, 80 . It is therefore imperative to develop an in vitro model that allows for simple
manipulation of the microenvironment, while still providing equivalent 3D conditions for
more accurate modeling of HNSCC. There are many chemotherapeutic drugs available for
treatment of HNSCC; however, for our studies we chose a well-established
chemotherapeutic drug that is clinically used for many cancer types, including HNSCC,
but is also known to elicit resistance in clinical applications 78 . Paclitaxel or Taxol® is a
chemotherapeutic drug prepared from extracts of the bark of Taxus brevifolia, and has been
used clinically for treatment of cancers such as breast cancer, non-small cell lung cancer,
!
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ovarian cancer, melanoma and HNSCC

!

81-83

. Taxol is able to bind to microtubules,

preventing their depolymerization, and therefore stabilizing and rearranging the
cytoskeleton and arresting cells in the G2 or M phase of the cell cycle. Horwitz and
colleagues reported that the affected cells are reported to either undergo apoptosis or
remain in a growth-arrested state

84

. Our preliminary studies show that HN12 cells

cultured in 2D are sensitive to therapeutic doses of Taxol, whereas they are resistant to
other commonly used chemotherapeutic drugs as cisplatin 36 .

TAXOL
!

Taxol was isolated from the bark of the western yew, Taxus brevifolia. It showed
cytotoxic activity against 9KB cells and multiple leukemia systems, and therefore was
reported as a possible antileukemic and tumor inhibitor by Monroe Wall, who reported its
structure in 1971. Taxol (C47H51NO14) has the molecular weight of 853.906 g/mol 85 .
Figure 1.5 illustrates the chemical structure of Taxol. It was shown to inhibit cell division
of HeLa cells and arrest the HeLa cells in late G2 and/or M phases at 0.25µM Taxol after
20 hours of incubation with the first report on the mechanism of action, reported by
Horwitz in 1979 86 . Horwitz and colleagues reported, that Taxol promoting microtubule
assembly in a dose dependent manner. They also showed lack of depolymerization of
!
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assemble microtubules in the presence of Taxol, leading to the conclusion that Taxol
stabilizes microtubules 86 . Further studies reported in 1981 showed that Taxol binds to
tubulin 87 . It was then used in animal experiments, with the then novel athymic mice.
Human tumors were implanted as xenografts, and then the animals were treated with daily
subcutaneous Taxol injections (12mg/kg) for 5 days a week over 3 weeks. The animal
study showed reduction in tumor burden with breast cancer, oral cancer, and bronchial
carcinoma transplants, but low antitumor activity against transplanted colon tumor 88 .
Further animal studies with transplanted human tumors showed that Taxol was able to
reduce tumor volumes for breast, endometrial, ovarian, brain, lung and tongue tumor
xenografts

89

. Taxol is a highly lipophilic substance requiring Cremophor EL® for

solubilization for intravenous injections. Due to its lipophilic properties it easily passes
through the plasma membrane 90, 91 . Subsequent human trials with up to 30% response
rate to the drug led to the FDA approval of using Taxol for treatment of ovarian cancer and
then later the same year for breast cancer 90, 92 . Taxol is currently used as either a single
agent or in combination with other cytotoxic drugs for the treatment of ovarian cancer,
breast cancer, head and neck cancer and lung cancer 93 . The relative response rate for
Taxol therapy for head and neck cancer is around 35-40%, based on multiple clinical trials
93

.
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ANGIOGENESIS IN HNSCC
!

The importance of angiogenesis or the formation of new blood vessels from
existing vasculature for tumor progression has been documented by Goldman as early as
1908

94

. Further studies in 1968 demonstrated that tumors are capable of secreting

diffusible angiogenic factors to promote angiogenesis 1 . In 1971 Folkman's pioneering
work lead to the angiogenic switch hypothesis as well as the discovery of the ‘tumor
angiogenesis factor’, which is now know as vascular endothelial growth factor (VEGF)
95, 96

1,

. He hypothesized that solid primary tumors between 1-3 mm3 are avascular for

prolonged periods of time, until they initiate the angiogenic process leading to increased
blood supply allowing for a larger tumor volume receiving adequate nutritional support 1,
95

. It is now believed that the angiogenic switch occurs when the effect of the pro-

angiogenic molecules overtakes the effect of angiostatic molecules

1

. Petruzelli et al.

showed that there is evidence of induction of blood vessel formation in HNSCC by
performing a chick chorioallantoic membrane angiogenesis assay, resulting in increased
angiogenic response in xenografts of human HNSCC samples compared to normal control
tissues

1, 97

. Regulation of angiogenesis is believed to be the rate-limiting step in

tumorigenesis 1 , therefore angiogenesis is one of the critical steps necessary for tumor
progression, and the study of the mechanisms of the angiogenic switch and blood vessel
recruitment is an active area of cancer research 98 .
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There are several important released factors that are involved in tumor invasion and
angiogenesis including CXCL5 and VEGF-A

99, 100

.

CXCL5 belongs to the CXC

chemokine family, which are heparin binding proteins. The highly conserved motif of first
two cysteines separated by a non-conserved amino acid residue, distinguishes this family
of chemokines from other chemokine families. The presence of the Glu-Leu-Arg (ELR)
motif on the NH2 terminus of the CXC chemokine indicates whether it is an angiogenic or
angiostatic if the ELR motif is absent 101 . CXCL5 is an angiogenic chemokine that is
reportedly overexpressed in a number of human tumors such as head and neck squamous
cell carcinoma, gastric, colorectal, prostate and lung cancer as wells as overexpressed in
lung tissue of patients with pulmonary fibrosis. CXCL5 was found to be upregulated in a
multitude of inflammatory response processes including non-pathologic responses to either
viral or bacterial induced inflammatory response. It was also found to play a significant
role in inflammation prevalent in diseases such as acute coronary syndrome, allergy,
rheumatoid arthritis, ulcerative colitis, pulmonary sarcoidosis, and pancreatitis. Elevated
levels of CXCL5 have also been implicated in endometriousis 102-121 .
It has been reported that metastatic HNSCC cells express relatively high levels of
CXCL5 compared to primary tumor cells measured by microarray. Western blot analysis
of conditioned medium and quantitative real-time PCR analysis of tumor cell lines from
primary-metastasis pairs confirmed the initial observations of elevated CXCL5 in cell lines
derived from metastatic tumors. Biological consequences of CXCL5 overexpression have
!
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been investigated in terms of tumor cell proliferation and motility. It was determined that
tumor cell proliferation and motility are reduced if CXCL5 expression is reduced. In vivo
modulation of CXCL5 showed that eliminating CXCL5 expression in metastatic cells also
eliminated their tumorigenic potential. CXCL5 expression was shown to be up-regulated in
invasive HN12 cells compared to cells derived from a less aggressive synchronous primary
tumor. Down-regulation of CXCL5 has been shown to reduce HN12 cell proliferation rate
and invasive ability in vitro, and to abrogate their tumorigenic potential in vivo

105

.

CXCL5 has also been shown to promote angiogenesis in a variety of other cancers 111 .
VEGF-A is a vital angiogenic cytokine with a central role in both normal and
pathogenic angiogenesis 1 . It has been shown to induce angiogenesis primarily by acting
on microvascular endothelial cells, enhancing their proliferation and migration resulting in
increased and propensity to form new capillaries 122 . There are many studies showing
VEGF-A up-regulation in the large majority of human tumors including HNSCC

1

.

Increased expression of VEGF-A and its primary receptor VEGFR-2 have been show in
cases of HNSCC of the oral cavity and the larynx, compared to normal tissue controls. 1
Further studies in patients found that tumor-infiltrating cells, such as macrophages and
plasma cells also exhibited elevated levels of VEGF-A expression. There is also a notable
correlation between VEGF expression and increases in microvasculature density 1 . A
bleak prognosis is highly correlated with elevated levels of VEGF expression in HNSCC 1
.
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Chapter 2: Hypothesis and Specific Aims
HYPOTHESIS
Cryogenic electrospun silk scaffolds will provide the necessary extracellular matrixmimicking support for a three-dimensional, in vitro head and neck squamous cell
carcinoma model.

SPECIFIC AIMS
Specific Aim 1: Develop an in vitro HNSCC 3D model and validate the model in terms
of epithelial differentiation
Rationale: HNSCC accounts for 7% of all new cancer occurrences, and has a high
morbidity and recurrence rate in spite of currently available treatments!&*( . It is therefore
important to further study tumorigenic mechanisms of this type of cancer in order to gain a
better understanding of tumor development and progression. Current in vitro models either
fail to be representative of the three-dimensional environment that support tumor
development in vivo or have not been rigorously validated to be representative of the in
vivo human tissue supporting tumor growth. It is therefore imperative to develop and
validate such a model!& .
Our preliminary work has shown that cryogenic electrospun silk can be used for
supporting 3D culture of HNSCC cells in co-culture with immortalized fibroblasts. We
therefore hypothesize that co-culture of HNSCC derived cell lines with a supporting
!
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fibroblast cell line on cryogenic electrospun silk scaffold could be a representative in vitro
model. HN12 cells have been derived from the lymph node metastasis of a human patient
with a primary HNSCC, and have been shown to be tumorigenic in a mouse model!(" . This
cell line has been well characterized in our and other laboratories!&*T!((T!("T!&+,T!&*(T!&*" . Human
foreskin fibroblasts have been immortalized with human telomerase in Dr. Holt’s
laboratory and have been generously donated. The immortalized nature of these cells is
desired for reduction of variability in cell line behavior from passage to passage!() , and
therefore repeatable behavior on scaffolds in the model. Validation of this model was
accomplished by comparing this model to tumor samples from HN12 cells grown in
immune-suppressed mice. Since HN12 cells are tumorigenic in a murine model, and
interact in 3D in a microenvironment that also incorporates interaction with the host on a
tissue and organism level, comparison of the in vitro model to this in vivo model is the
closest possible way of validating the in vitro model. Using HN12 cells in both in vitro and
in vivo conditions controls for possible variation between different HNSCC cell lines.
Specific Aim 2: Compare drug resistance of the 3D model compared to 2D monolayer
Rationale: Various studies have shown that tumor cells grown in 2D monolayer
culture are much more sensitive to chemotherapy drugs than the same cells grown in
various 3D models such as spheroids or porous microspheres! "+T! )'T! )) . This finding is
consistent with in vivo studies showing lower drug sensitivity than expected based on in
vitro studies. We hypothesize that drug resistance of HN12 cells will be higher when they
!
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are grown in our 3D model than in 2D monoculture. Taxol is a well-studied chemotherapy
drug used for a variety of cancers including head and neck carcinomas!.( , therefore it can
serve as a representative drug for determining if there is a difference between HN12
survival in 2D vs 3D culture in response to chemotherapy drug treatment. HN12 cells have
been shown to be resistant to some commonly used drugs such as cisplatin! (' but no
literature exists on HN12 cell resistance to Taxol, however our preliminary results showed
that they are sensitive to Taxol when cultured in 2D culture conditions. A difference in
tumor cell survival in response to the representative drug in 2D and 3D conditions would
further validate the 3D model if the cells are more sensitive in 2D than 3D conditions,
indicating further consistency with clinical observations of low response to chemotherapy.
Specific Aim 3: Evaluate angiogenesis potential of the 3D model
Rationale: Switch to an angiogenic phenotype is critical for tumor progression. Tumor
growth past a critical size requires tumor cells to promote angiogenesis. Angiogenic factor
release is often upregulated in tumor cell capable of inducing angiogenesis. HN12 cells
have been shown to be capable of angiogenesis when implanted in nude mice and have
been shown to secrete factors that promote angiogenesis. Therefore we investigated the
angiogenic potential of HN12 cells grown in our 3D tumor model by measuring the
angiogenic factor release.
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Chapter 3: Materials and Methods

SCAFFOLD FABRICATION
Silk Extraction. Silk extraction from Bombyx mori silkworm cocoons was
performed using a previously reported method 55 . Silk cocoons were boiled in 0.02M
Na2CO3 for 30 min, washed and then dissolved in 9.3M LiBr. The silk-LiBr solution was
dialyzed against 18.2M#-grade water with 6 changes over 3 days in order to remove LiBr
from the solution. The silk solution was then centrifuged to remove remaining impurities,
and the purified silk solution lyophilized.
Conventional Electrospinning. Conventional electrospinning of silk

65

was

performed by dissolving freeze-dried silk in 1,1,1,3,3,3-hexafluoro-2-propanol (HFP) at a
concentration of 12% (w/v). A syringe of this solution was placed in an electrostatic field
with 25kV applied to an 18 gauge blunt needle, while an aluminum collecting mandrel
remained grounded 20cm away from the needle. The collecting mandrel was a hollow
cylinder with a 4cm outer diameter and 11cm in length with a wall thickness of 2mm. The
solution was dispensed from the syringe at a rate of 11ml/h into the electrostatic field while
electrospun fibers accumulated on the rotating (500rpm) and translating (2cm/s over 7 cm)
mandrel at ambient temperature in an atmosphere of 33% humidity. Humidity inside the
electrospinning chamber was monitored with a humidity meter (Fisher Scientific,
Pittsburg, PA) and adjusted with an evaporative humidifier (Vornado, Andover, KS).
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Cryogenic Electrospinning. Cryogenic electrospinning was performed based on
previously described methods for synthetic polymers

52, 58-61

. The parameters for

conventional electrospinning were applied to cryogenic electrospinning with the exception
that the temperature of the collecting mandrel was maintained below 0ºC with dry ice
occupying the entire inside volume of the collecting mandrel. The mandrel was pre-chilled
with dry ice for 1 hour prior to refilling with fresh dry ice and immediate electrospinning
for 30 minutes. The cryogenically electrospun silk scaffold was then freeze-dried
immediately in order to prevent thawing of the collected ice.

CELL CULTURE
Human telomerase reverse transcriptase (hTERT)-immortalized human foreskin
fibroblasts (BJ-hTERT) were a gift from Dr. S. Holt (Dept. of Pathology, VCU) 37 . These
cells were propagated in DMEM (Thermo Fisher, Asheville, NC) with 10% (v/v) calf
serum (Thermo Fisher, Asheville, NC), 100 Units/mL of penicillin and 100µg/mL
streptomycin (Thermo Fisher, Asheville, NC), 3% 1X 199 medium (Sigma-Aldrich, St.
Louis, MO), and 1mM sodium pyruvate (Thermo Fisher, Asheville, NC). HN12 human
head and neck squamous cell carcinoma cells were maintained as previously described 35 .
They were propagated in DMEM, with 10% (v/v) calf serum, 100 Units/mL of penicillin
and 100µg/mL streptomycin and 1mM sodium pyruvate. Previously constructed and
selected HN12 cell lines with reduced expression of CXCL5 or CXCR2 (shCXCL5 and
shCXCR2) and empty vector, non-targeting controls were also maintained as the parental
!
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HN12 cells 105 . The spontaneously immortalized human oral keratinocyte cell line NOKSI
(a gift from Dr. J.S. Gutkind, NIDCR, Bethesda, MD) and hTERT-immortalized HFK-398
human foreskin keratinocytes 38 were maintained in defined serum-free medium (K-SFM;
Invitrogen, Carlsbad, CA). Telomerase immortalized microvasculature endothelial (TIME)
cells (ATCC, Manassas, VA) were propagated in EBM-2 with EBM-2 growth supplements
(Lonza, Walkersville, MD)
Fluorescently-labeled cells were generated by nucleofection as described
previously 35 . BJ-hTERT cells were nucleofected with a pCEFL-YFP plasmid that directs
expression of yellow fluorescent protein (YFP). HN12 and NOKSI cells were similarly
nucleofected with pCEFL-mCherry to generate cells with red fluorescence. Cell
populations expressing high levels of fluorescent proteins were isolated by selection in
400$g/ml G418 followed by single colony manual selection. G418 selected populations
were seeded at an extremely low densities and after colonies were formed, the fluorescent
colonies were identified via fluorescence microscopy. The chosen colonies were
trypsinized by placement of a cloning ring around the colonies, and only detaching the
cells isolated by the cloning ring. These fluorescent populations of cells were then
propagated under G418 selection and used for further experiments.
Scaffold disks were prepared using 10mm diameter tissue biopsy punches from
electrospun silk mats. Disks were placed into 48 well plates, disinfected with 70% ethanol,
and washed with PBS prior to cell seeding. Ethanol treatment causes "-sheet formation and
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was critical to prevent subsequent solubility in aqueous solutions 65 . Fibroblasts were
trypsinized, washed, re-suspended and 1x106 cells added per disk. In co-culture
experiments, fibroblasts were cultured on the scaffolds for one week prior to seeding of
2x105 NOKSI, 2x105 HFK-398 or 1x105 HN12 cells on the same side of the scaffolds as
previous seeding of the fibroblasts. Cell numbers were chosen to match the cell numbers
reported in literature for the organotypic models of normal and transformed epithelium 2630

. After epithelial cell attachment, scaffolds were raised to the air-liquid interface as per

standard organotypic culture methodology, by placing the scaffolds in the upper chamber
of 0.4µm pore Transwell® inserts (Corning, Lowell, MA) and adding medium to the
bottom chamber

125

, such that the lower surface of the scaffold was in contact with

medium and the upper surface was exposed to air. HN12 and BJ co-cultures for HNSCC
modeling on cryogenic electrospun silk scaffolds, were not lifted to the air-liquid interface,
due to the in vivo nature of HN12 cells. These were isolated from a lymph node tumor that
had no interface with air, therefore exposure to air for these cells would further remove
them from their native environment. All co-cultures with HFK-398 and NOKSI cells were
maintained in K-SFM. All cultures and co-cultures with TIME cells were maintained in
EBM-2. HN12 and BJ-hTERT co-cultures were maintained in DMEM.

SCANNING ELECTRON MICROSCOPY
Scanning electron microscopy (SEM) was performed on dry scaffolds to evaluate
the morphology of the scaffolds generated by the two electrospinning methods. It was also
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performed on decellularized tumor ECM samples, which were freeze-dried. Dry samples
were gold sputter coated and imaged with a Zeiss EVO 50 XVP scanning electron
microscope (Nano Technology System Division, Carl Zeiss Microimaging Inc.,
Thornwood, NY). Average fiber width data were obtained from the SEM images of the
scaffolds and tumor ECM using a custom image-processing program as previously
described 126 and independently confirmed using ImageTool3.0 (Shareware provided by
UTHSCSA) as previously described 65 .

MECHANICAL TESTING
Uniaxial tensile testing of electrospun scaffolds was performed as previously
described21. Each scaffold type was dehydrated in 70% ethanol for 30 minutes and allowed
to air dry for 2 hours. Dog-bone shaped samples (overall length of 20 mm, 2.67 mm at the
narrowest point, gauge length of 7.5 mm, n=10) were punched from the two types of
scaffolds perpendicular to the direction of mandrel rotation. Uniaxial testing was then
performed using an MTS Bionix 200 testing system with 100 N load cell (MTS Systems,
Eden Prairie, MN). Samples were pulled uniaxially, along the longest axis of the samples
to failure at the rate of 10 mm/min (1.33min-1 strain rate). TestWorks version 4 was used to
record the readings and calculate peak stress, modulus and strain at break 65 .
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POROSITY
Porosity was determined using the liquid intrusion method 127 . Briefly, ethanol pretreated then dried scaffold disks (n=10) were weighed and then submerged in water
overnight. The scaffolds were then removed from water and reweighed. Porosity was
calculated as the ratio of volume of intruded water to the sum of the volume of the intruded
water and the volume of the scaffold. Densities of water and silk fibroin of 1g/cm3 and
1.43g/cm3, respectively, were used to determine the volumes

128

.

RNA EXTRACTION
HN12 cells were seeded on to cryogenically electrospun scaffolds and cultured for
24 hour prior to RNA extraction. Scaffold disks were moved to new wells prior to RNA
extraction to avoid extraction from cells attached to the plate and not the scaffolds. In order
to see if RNA extraction would improve with additional scaffold/cell material per volume
of Trizol reagent (Life Technologies, Carlsbad, CA), there were extraction samples of 1
scaffold disk, 3 scaffold disks and 5 scaffold disks (in triplicate) as well as negative control
samples with unseeded scaffolds, and positive control samples of HN12 cells plated on
tissue culture plastic. 1mL of Trizol reagent was added to each sample, and samples were
incubated for 5 minutes and vigorously pipetted to break up the scaffolds in order to allow
for improved cell interaction with Trizol. The samples were then subjected to three
freeze/thaw cycles. Chloroform (200 !L) was added to the samples, then the tubes were
shaken by hand, and centrifuged at 4°C for 15 min at 12,000 x g. The aqueous phase was
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collected for further analysis. The collected aqueous samples were combined with 0.5mL
of isopropanol for 10 minutes and centrifuged for 5 minutes at 12,000xg at 4°C. The
supernatant was discarded, while the pellets were washed with 1 mL of 75% ethanol and
again centrifuged for 5 minutes at 12,000xg at 4°C. The supernatant was again discarded,
while the pellets were air-dried for at least 30 minutes and resuspended in 20 !L of RNasefree water. The samples were then heated for 15 minutes at 55°C and cooled on ice for 2
minutes. RNA concentrations were measured via the Nanodrop spectrophotometer.

WESTERN BLOT
Cell lysates from scaffolds seeded with 50,000 HN12 cells or unseeded scaffolds
were obtained by washing the disks with cold PBS twice, then incubated in lysis buffer (50
mM N-2-hydroxyethylpiperazine-N’-2-ethane- sulfonic acid, pH 7.5, 150 mM NaCl, 1
mM ethylenediaminetetraacetic acid, 0.1% Tween-20, 1 mM phenylmethylsulfonyl
fluoride, 20 µg/ml aprotinin and 20 µg/ml leupeptin) on ice for 20 minutes. Samples were
centrifuged at 4°C for 10 minutes at 12,000 x g, and supernatants with the cell lysates were
moved to new tubes. Protein concentration was measured using the Bradford method
(BCA Protein Assay Reagent; Bio-Rad, Hercules, CA). Protein lysate samples with 80µg
of protein were combined with 6x SDS-PAGE (120 mM Tris-HCl, 600 mM NaCl, 420
mM EDTA, 12% SDS) loading buffer, boiled for 10 minutes at 100°C, then cooled on ice
for 2 minutes. The denatured proteins samples were then loaded into the wells of the 10%
(w/v) polyacrylamide gel, and gel electrophoresis was performed at 120 V in 1X SDS!
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PAGE (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 70 mM EDTA, 2% SDS) running buffer.
Resolved proteins were transferred to a polyvinylidene difluoride membrane (ImmobilonP, Millipore Corporation, Bedford, MA) for 24 hours. Blocking of the membranes was
performed with 5% non-fat dried milk in Tween-Tris buffered saline (TTBS) (10 mM
Tris–HCl, pH 7.6, 0.5% Tween-20 and 150 mM NaCl) for 1 hour at room temperature.
The mouse primary antibody for EPS8 (E-18220, BD Transduction Laboratories, San
Diego, CA) was diluted to 150 ng/ml in blocking buffer and was incubated with the
membrane overnight at 4°C. The membranes were washed with TTBS three times for 5
minutes on a shaker, then incubated with the anti-mouse horseradish peroxidaseconjugated secondary antibody (MP Biomedical, Aurora, OH) diluted 1:10,000 in blocking
buffer, at room temperature for 1 hour. After incubation with the secondary antibody, the
membranes were washed again, three times for 5 minutes with TTBS. The Western
Lightning™ Plus ECL chemilumimescence reagent (Perkin Elmer Life Sciences Inc.,
Boston, MA) was added to the samples for 2 minutes and Kodak film was exposed to the
membranes for imaging of the bands. The above procedure was repeated for probing for
actin, with an anti-actin antibody (SC-1616, Santa Cruz Biotechnologies, Santa Cruz, CA)
diluted 200 ng/ml in blocking buffer, and then an anti-goat horseradish peroxidaseconjugated secondary antibody (MP Biomedical, Aurora, OH) diluted 1:10,000 in blocking
buffer.
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FLUORESCENCE MICROSCOPY
For fluorescence microscopy, samples were fixed in cold methanol for 20 min,
washed 3 times in PBS, flash frozen, embedded in Neg50 frozen section medium (Thermo
Fisher, Asheville, NC), cryosectioned at 10$m and mounted on glass slides. Samples were
counterstained with 4’,6-diamidino-2-phenylindole (DAPI), mounted in Vectashield Hard
Set (Vector Laboratories, Burlingame, CA) and examined using a Zeiss Axiovert 200M
fluorescence microscope (Carl Zeiss Microimaging, Inc, Thornwood, NY).

Scaffold

thickness was also measured from the cryosections under phase contrast for each scaffold
(n=10).

LIVE/DEAD ANALYSIS
Samples were stained with 5-chloromethylfluorescein diacetate (CMFDA) for
viable cells and ethidium homodimer-1 (EthD-1) for dead cells, as established previously
129

. After 21 days in culture, disks were incubated with 10µM CMFDA and 5µM EthD-1

for 40 minutes and then washed in PBS three times for 5 minutes, fixed in 4% PFA,
cryosectioned and imaged as described above. Viability was calculated by counting the
percentage of viable cells per field of view from five randomly chosen fields of view per
sample from three samples per condition at 200X magnification.
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IMMUNOFLUORESCENT STAINING
Samples were fixed in cold methanol, permeabilized in 0.1% Triton X-100,
blocked in 5% bovine serum albumin (BSA) for one hour at room temperature, then
incubated with either anti-Ki67 antibody (clone B56; Dako, Carpinteria, CA), or anti-pankeratin antibody (clone AE1/AE3; Thermo Fisher, Asheville, NC), or anti-involucrin
(clone SY5; Thermo Fisher, Asheville, NC) antibody, or anti-vimentin antibody (Sigma,
St. Louis, MO), or anti-EGFR antibody (SC-03, Santa Cruz Biotechnologies, Santa Cruz,
CA) diluted to 2 µg/ml in 5% BSA overnight at 4°C. Samples were then washed three
times in PBS with 0.1% Tween for 5 minutes each. Anti-mouse and anti-rabbit FITCconjugated secondary antibodies (Vector Laboratories, Burlingame, CA) were applied at a
dilution of 1:500 for one hour at room temperature to appropriate primary antibody
counterparts.

The samples were washed with PBS five times and then frozen,

cryosectioned and imaged as described above.

DRUG DOSE RESPONSE STUDY
The IC90 for two-dimensional culture of HN12 cells in monolayer was determined by
the crystal violet staining assay. 1x105 HN12 cells were seeded into wells of 6 well plates
and grown until 80% confluent. Increasing concentrations of Taxol, or DMSO as a control,
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were applied to the wells in triplicate and cells were allowed to grow for 72 hours. Cells
were then washed with PBS, fixed with methanol and stained with 0.1% crystal violet in
PBS for 40 minutes. Unbound crystal violet was then washed away with six consecutive
five-minute washes with PBS. The dye was extracted in 100% ethanol and the optical
density for each sample determined at 600 nm in a spectrophotometer. The percentage of
viable cells was quantified by dividing the mean absorbance of treated cells by the mean
absorbance readings for the controls. A dose response curve was plotted to determine the
Taxol concentration that resulted in 90% cell death. This concentration of Taxol was used
for further studies.

ELISA for CXCL5 and VEGF-A:
Enzyme-linked immunosorbent assay (ELISA) kits for both CXCL5 and VEGF-A
were purchased and sample analyses were performed according to the kit manufacturer’s
instructions (R&D Systems, catalog numbers DX000 and QVE00B, respectively). Briefly,
microplates were coated with the capture antibodies for CXCL5 or VEGF-A overnight at
room temperature. Standards and samples were added to the coated wells and the factor of
interest bound to the plate by immobilized antibody. Unbound proteins were washed away
with washing buffer (0.05% Tween®20 in PBS) at room temperature. Enzyme-linked
polyclonal detection antibody specific for CXCL5 or VEGF-A was added to the wells.
Unbound antibodies were washed away with wash buffer at room temperature. The TMB
(tetramethylbenzidine) substrate solution was then added. Color developed proportional to
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the amount of enzyme present, and the reaction was stopped by addition of 2N H2SO4.
Color intensity was measured using an absorbance plate reader at 450 nm. The standards of
known protein concentration and measured absorbance were then used as positive controls
and to calculate the unknown sample concentrations. Samples with media with no CXCL5
or VEGF-A, and samples of water, were used as negative controls and blanks respectively.

DECELLULARIZATION OF TUMOR ECM
The decellularization method of tumor specimens was adapted from a previously
described method for decellularization of human umbilical arteries! &(+ . Frozen tumor
specimens were cryosectioned into 100 micron thick pieces and thawed and washed in
sterile PBS for 5 minutes. The samples were then incubated in CHAPS buffer (8mM
CHAPS, 1M NACL, and 25mM EDTA in PBS) for 24 hours at 37°C and washed with
PBS three times for 5 minutes at room temperature. The samples were then incubated with
an SDS buffer (1.8mM SDS, 1M NaCl, 25mM EDTA in PBS) for 24 hours at 37°C.
Samples were extensively washed with PBS for 5 washes, 15 minutes each. Then samples
were incubated with endothelial basal medium -2 (EBM-2, Lonza Walkersville, MD) for 2
days at 37°C, and washed with sterile H2O for another round of 5 washes, 15 minutes each.
The samples were then flash frozen to -80°C for 1 hour and freeze-dried overnight for
scanning electron microscopy analysis.
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CONDITIONED MEDIUM EXPERIMENTS
Telomerase immortalized microvasculature endothelial (TIME) cells (ATCC,
Manassas, VA) were cultured in EBM-2 with EBM-2 growth supplements (Lonza,
Walkersville, MD) on tissue culture plastic until 80-90% confluency (~4x106 cells per
plate). The cells were washed in PBS twice, and EBM-2 with growth supplements,
omitting the VEGF supplement was replaced. The cells were cultured for 48 hours, then
the conditioned medium was collected and sterile filtered with a 0.2 micron sterile filter.
The medium was aliquoted and stored at -20°C until further use.
HN12 cell lines seeded in 12 well plates with 10,000 cells/well and cultured under
normal conditions for 48 hour until 80% confluency. The attached cells were then washed
with PBS extensively and cultured either with fresh EBM-2 with supplements (omitting
the VEGF supplement), or with TIME-conditioned EBM-2 for 48 hours. The medium was
then collected for ELISA analysis for CXCL5 and VEGF presence. The cells were
trysinized and counted to normalize the ELISA results to the number of cells producing the
released factors.

STATISTICAL ANALYSIS
All quantitative data between our in vitro model and various controls were
compared using a one tailed, paired student t-test or a one-way analysis of variance
(ANOVA) with p<0.05 considered to be statistically significant. When ANOVA analysis
resulted in statistically significant differences, the Tukey-Kramer test was performed to
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determine which data sets were significantly different. All quantitative data are presented
with the standard error of the mean (s.e.m.).
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Chapter 4: Cryogenic Electrospun Silk for Mucosal Modeling

Preface: The following section has been published in Journal of Biomedical Materials
Research: Part A, December 2011 131

INTRODUCTION

Electrospinning is a commonly used biomimetic technique for creating
extracellular matrix analogues that can be used for three-dimensional in vitro cell culture
as well as for implantable tissue constructs. Many natural and synthetic polymers have
been electrospun for the purpose of simulating native tissue cell-matrix interactions 132-138 .
One natural material that is frequently used for tissue engineering purposes is silk fibroin,
due to its biocompatibility and mechanical properties 48 , as well as structural similarities to
collagen 49 . Electrospun silk has been used for various tissue engineering applications
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including in vitro keratinocyte-fibroblast co-culture with excellent cell adhesion to the
surface of the scaffolds 50 .
One major drawback to the application of electrospun scaffolds is limited cell
infiltration and therefore limited three-dimensional cell-cell and cell-matrix interactions, as
well as limited vascular ingrowth potential upon implantation of such constructs due to
restricted void space between fibers 51, 58 . Possible solutions to increasing cell infiltration
into electrospun scaffolds include electrostatically spraying cells into a nascent scaffold
during the electrospinning process 53 . While this method is effective at integrating cells
throughout the entire volume of the scaffold, vascular ingrowth potential remains poor due
to lack of adequate void space for cell migration 51 . Another approach to increase porosity
and therefore increase cell infiltration is the inclusion of sacrificial fibers that can be
dissolved after scaffold electrospinning is complete 54, 55 . Minimal cell infiltration has
been shown with this method 55 . The cotton-ball electrospinning technique has also been
applied to improve cell infiltration with positive results for one week of in vitro cell culture
56

. Low-temperature electrospinning, also known as cryogenic electrospinning, is a

promising technique that addresses the issue of increasing void volume between
electrospun fibers and therefore facilitating cell infiltration throughout the entire volume of
the electrospun scaffolds 52, 58, 59 . Cryogenic electrospinning uses ice crystals throughout
the growing scaffold to prevent formation of highly compacted fibers during the
electrospinning process. The ice crystals are then removed by freeze-drying the scaffolds,
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leaving large void spaces for cell infiltration. The resulting scaffolds support cell
infiltration in vitro and vascularization in vivo 52, 58, 60, 61 .
Although conventional electrospun silk has been utilized for various tissue
engineering purposes, poor cell infiltration has been a consistent limitation for using these
types of scaffolds in biomimetic applications requiring true three-dimensional cell-scaffold
interactions. In the present work, we have used cryogenic electrospinning of silk to
generate scaffolds that support growth of fibroblast-epithelial co-cultures in an in vitro,
three-dimensional model.

RESULTS

Morphology of Scaffolds
Scaffold morphology was evaluated by SEM in order to visualize the structure of
the scaffolds. As shown in Figure 4.1, conventional electrospun silk scaffolds consisted of
randomly oriented, densely packed, non-woven fibers, whereas cryogenic electrospun silk
scaffolds contained randomly oriented non-woven fibers with qualitatively more open
structure. In order to quantify difference between the openness of each type of scaffold,
porosity analysis was performed. The porosity was determined to be 88±0.6% and
93±0.08% for conventional and cryogenic electrospun scaffolds, respectively (p<0.001).
Fiber widths were determined to be 2.58±0.06µm and 3.61±0.36µm for the cryogenic and
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conventional scaffolds respectively. Scaffold thickness was measured to be 497±6µm and
533±7µm for cryogenic and conventional scaffolds respectively.
Uniaxial tensile testing
As shown in Figure 4.1C, there were statistically significant differences in
mechanical properties between cryogenic and conventional electrospun silk scaffolds in
terms of peak stress and modulus. Cryogenic electrospun silk was shown to be 3.5 fold
weaker than the conventional electrospun silk. However, there was no significant
difference between the strain at break for both scaffolds (p=0.0863).

Fibroblast infiltration of scaffolds
In order to evaluate the potential for cell infiltration throughout the volume of the
scaffolds, BJ-hTERT fibroblasts were seeded on cryogenic electrospun and conventional
electrospun silk scaffolds, and maintained in culture for up to 21 days. Cell distribution is
shown in Figure 4.2, which shows DAPI staining of transverse cryosections of fixed
scaffolds. Conventionally electrospun silk scaffolds supported attachment of BJ-hTERT
fibroblasts on the seeding surface with no apparent cell infiltration to the interior of the
scaffolds. In contrast, cryogenically electrospun scaffolds supported a wide cell
distribution throughout the entire depth of the scaffold.
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F#GH:4!."/!A-D: BJ-hTERT fibroblasts on cryogenic electrospun scaffolds after 14 and 21 days of culture (A,
B), and on conventional electrospun scaffolds after 14 and 21 days (C, D) respectively.!
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Co-culture studies
Co-culture experiments were performed to show the potential of using the novel
scaffold for multiple in vitro 3D culture applications, such as mucosal modeling of either
normal growth or tumor cell invasion. BJ-hTERT/YFP fibroblasts were seeded onto
cryogenic or conventional electrospun scaffolds and allowed to grow for one week prior to
the addition of mCherry-transfected epithelial cell lines onto the surface of the scaffold
disks, in order to allow for separate epithelial and connective layer formation mimicking
epidermal and dermal cell composition respectively. Co-culture systems were maintained
for up to 21 days prior to fixation, cryosectioning and microscopic analyses.
As shown in Figure 4.3, BJ-hTERT and HN12 cells were found to have infiltrated
the entire volume of the cryogenic electrospun scaffolds. The corresponding conventional
electrospun scaffolds did not support cell infiltration, with cell attachment only to the
superficial/seeding surface of the scaffolds even after 14 days of co-culture.
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Figure 4.3. HN12/mCherry and BJ-hTERT/YFP co-culture on cryogenic electrospun scaffolds at (A) 7
and (B) 14 days of co-culture, and on conventional electrospun scaffolds at (C) 7 and (D) 14 days of co-culture.
Note autofluorescscence of the silk scaffolds in the red channel.
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NOKSI cells form a multi-cell layer on the seeding surface of the cryogenic
electrospun scaffolds with fibroblasts distributed throughout the scaffolds, as shown in
Figure 4.4. In contrast, attachment of both NOKSI and BJ-hTERT fibroblasts to the
conventional electrospun scaffolds is restricted to the surface of the scaffolds with no
apparent infiltration of the scaffold interior by the fibroblasts.
NOKSI cells show anti-keratin immunoreactivity in the cryogenic scaffold (Fig.
4.5A). Ki67 was robustly expressed, indicating the proliferative nature of these cells (Fig.
4.5C). However, expression of involucrin, a marker of epithelial terminal differentiation,
was negligible (Fig. 4.5E), suggesting that NOKSI cells may be unable to differentiate in
this system.
In order to determine whether cryogenic silk scaffolds are capable of supporting
epithelial differentiation, co-culture of HFK-398 cells with BJ-hTERT fibroblasts was
carried out under the same conditions as NOKSI co-cultures described above. As shown in
Figure 4.6, whereas the HFK-398 epithelial cells on cryogenic silk scaffolds also showed
high expression of keratin, in contrast to NOKSI cultures expression of the proliferation
marker Ki67 was low, and involucrin expression was high, consistent with cell cycle exit
and entry into a terminally differentiated state. Taken together, these data suggest that
cryogenic silk scaffolds are able to support the terminal differentiation of keratinocytes
that are competent for differentiation, such as HFK-398.
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Figure 4.4. NOKSI/mCherry and BJ-hTERT/YFP co-culture on cryogenic electrospun scaffolds at (A) 7
and (B) 14 days of co-culture, and on conventional electrospun scaffolds (C) 7 and (D) 14 days of co-culture. Note
autofluorescence of the silk scaffolds in the red channel.
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Figure 4.5. Immunofluorescent staining of BJ-hTERT and NOKSI for keratin expression on (A) cryogenic
and (B) conventional scaffolds; for Ki67 expression on (C) cryogenic and (D) conventional scaffolds; and for
involucrin expression on (E) cryogenic and (F) conventional scaffolds. Immunofluorescent staining was performed
after 21 days of co-culture at the air-liquid interface (28 days of total culture).
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Figure 4.6. Immunofluorescent staining of BJ-hTERT and HFK-398 for keratin expression on (A) cryogenic
and (B) conventional scaffolds; for Ki67 expression on (C) cryogenic and (D) conventional scaffolds; and for
involucrin expression on (E) cryogenic and (F) conventional scaffolds. Immunofluorescent staining was performed
after 21 days of co-culture at the air-liquid interface (28 days of total culture).
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Viability of cells in electrospun silk scaffolds
Viability analysis of cells cultured on the scaffolds was performed to confirm that
the culture conditions were adequate to support long-term experiments. Live/dead analysis
was performed for cells cultured on cryogenic and conventional electrospun scaffolds as
shown in Figure 4.7A-H. Cell viability on cryogenic scaffolds was found to be
significantly higher (Fig. 4.7I) than cells cultured on conventional scaffolds. As shown in
Figure 4.7I, monoculture and co-culture systems consistently resulted in more than 90%
viability on the surface and throughout the volume of cryogenic scaffolds compared to less
than 90% viability on conventional scaffolds after three weeks of culture.

!

',!

!

!

!

F#GH:4!."+"!Z#12#3#9<!1?13<D#D!8=!>433D!8?!434>9:8D;H?!D#3R!D>1==83ID!1=94:!/&!I1<D!8=!>H39H:4"!U[M60S\0!8?!
NTQ!>:<8G4?#>!1?I!NUQ!>8?$4?9#8?13!D>1==83ID]!U[M60S\0!1?I!@A&/!8?!N5Q!>:<8G4?#>!1?I!N^Q!>8?$4?9#8?13!
D>1==83ID]!U[M60S\0!1?I!ALB_E!8?!NSQ!>:<8G4?#>!1?I!NFQ!>8?$4?9#8?13!D>1==83ID]!U[M60S\0!1?I!@F_M'),!8?!
!
''!
N`Q!>:<8G4?#>!1?I!N@Q!>8?$4?9#8?13!D>1==83ID"!

!

!

!

F#GH:4!."+!>8?9#?H4I!C!NEQ!J4:>4?9!$#12#3#9<!8=!>433D!1=94:!/&!I1<D!8=!>H39H:4!8?!
434>9:8D;H?!D#3R!D>1==83ID!N?W&-C!XYM!D"4"7"Q"

!
!
!
!
!
!
!

!

')!

!

!

!

DISCUSSION

Low temperature, or cryogenic, electrospinning has been previously reported to be
an effective technique for inducing cell infiltration into synthetic electrospun scaffolds 52,
58-61

. The current report demonstrates the application of this technique for the first time to

the natural polymer, silk. Cell distribution throughout the entire volume of the electrospun
silk scaffold was achieved only using the cryogenic electrospinning technique, whereas
conventional electrospun silk did not show the same structural properties and no cell
infiltration was observed. Fibroblast infiltration throughout the electrospun silk scaffolds
was only observed in cryogenically electrospun scaffolds. The three dimensional cell
culture conditions also allowed for variation in cell type distribution with the invasive
HN12 cells infiltrating the entire volume of the scaffolds, whereas the immortalized
keratinocytes formed multi-cell layers on the surface of the scaffolds at the air-liquid
interface (Fig. 4.3A&B). Poor fibroblast attachment and limited keratinocyte infiltration
were observed in co-culture experiments with conventional electrospun silk scaffolds, with
no formation of distinct cell layers (Fig. 4.3C&D). Co-culture systems of cryogenic
electrospun silk scaffolds seeded with fibroblasts and NOKSI cells exhibited two distinct
layers: a deeper fibroblast layer and a more superficial epithelial layer more reminiscent of
dermal and epidermal structures, respectively (Fig. 4.4B). Immunofluorescence staining
for keratin revealed low, evenly distributed keratin expression in the epithelial cells,
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confirming their lineage (Fig. 4.5A). The NOKSI cells showed high expression of the
proliferation marker Ki67 (Fig. 4.5C) even after three weeks in air-liquid interface coculture, but extremely low or undetectable levels of the terminal differentiation marker
involucrin (Fig. 4.5E). Thus, NOKSI cells may be defective in terminal differentiation. In
order to investigate further whether cryogenic scaffolds support epithelial differentiation,
we conducted similar co-culture experiments with the hTERT-immortalized HFK-398
keratinocytes, which have previously been shown to undergo terminal differentiation in
organotypic culture 38 . Similar to NOKSI cells, HFK-398 cells were immunoreactive with
a pan-keratin antibody (Fig. 4.6A). However, after three weeks of air-liquid interface
culture, Ki67 expression in HFK-398 cells was minimal and involucrin expression was
prominent, features that are consistent with epithelial differentiation (Figs. 4.6C&E).
Therefore, our data suggest that terminal differentiation of epithelial cells is possible on
cryogenic electrospun silk scaffolds, and this system may be useful for in vitro mucosal
modeling. In addition, co-culture systems of cryogenic scaffolds seeded with fibroblasts
and lymph node metastasis-derived HN12 cells resulted in the tumor cells occupying and
sharing the entire scaffold volume with the fibroblasts, raising the possibility that the silk
scaffolds may also show utility for in vitro investigation of tumor cell invasion.
Furthermore, all cells that we have tested have remained viable for at least three weeks,
with higher viability observed on cryogenic scaffolds, possibly due at least in part to
increased cell-cell and cell-matrix interactions in three dimensions compared to two
dimensions 16 .
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Fluorescent labeling of cells was used to facilitate identification of cell types in coculture experiments. Silk auto-fluorescence in the red region of the spectrum makes it
difficult to identify mCherry labeled cells, therefore DAPI was also used to counterstain
cell nuclei. Electrospun silk exhibited no auto-fluorescence in the ultra-violet or blue
regions of the spectrum. Although silk also fluoresces in the green region, the intensity of
the YFP signal was much greater than that of the scaffold, allowing a clear distinction of
YFP labeled cells. A major advantage of using fluorescently labeled cells is the ability to
differentiate between the cell types in co-culture systems. A disadvantage of using
fluorescently labeled cell lines is the possible variation in protein expression between
labeled and original cells lines. However, no notable differences in cell proliferation,
attachment or viability were observed between labeled and corresponding unlabeled
parental cell lines (unpublished observations); therefore, in these studies the labeled cells
seeded on scaffolds are predicted to behave in a similar fashion to the parental cell lines.
We found that maintaining relative humidity above 30% was a critical requirement
for creating electrospun silk scaffolds capable of inducing cell infiltration, a similar result
to that found with other cryogenic electrospun scaffolds 52, 58, 59 . Cryogenic electrospun
silk scaffolds that were manufactured at lower humidity levels did not support cell
infiltration and did not appear to differ appreciably from conventional electrospun
scaffolds, as judged by SEM analysis (unpublished observations). The cryogenic
electrospun silk fibers were measured to have narrower widths than conventional
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electrospun silk fibers. This observation might be attributable to a possible change in the
electric field during the electrospinning process due to ice accumulation on the mandrel, as
well as diameter change of the collecting mandrel. Another critical element of cryogenic
electrospinning of silk is maintaining the scaffold frozen until the sample is lyophilized.
Any melting of the ice crystals dissolves the electrospun silk, which does not become
insoluble in aqueous solution until after dehydration and ethanol treatment.
A common technique to increase porosity of electrospun scaffolds is to introduce a
sacrificial polymer into the electrospinning process. The sacrificial polymer, such as
poly(ethylene oxide), is mixed in the electrospinning solution with the polymer of interest,
such as silk. The solution of both polymers is electrospun conventionally and then the
sacrificial polymer is dissolved to leave a scaffold composed only of the desired material 54
. Although this procedure does result in increased void volume, minimal cell infiltration
has been demonstrated using this approach 55 . Thus, cryogenic electrospinning of silk
would appear to be advantageous. The porosity increase between cryogenic and
conventional electrospinning remains consistent from polymer to polymer as demonstrated
by previous studies and confirmed by this study 59 . Another recent method for increasing
porosity of electrospun scaffolds is the cotton-ball electrospinning method
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infiltration does appear to increase with this method compared to conventional
electrospinning. However, these studies were carried out over a 7-day period
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experiments in the present study show high cell viability after 21 days in culture.
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In the present study, we performed uniaxial tensile testing to characterize the
cryogenic electrospun silk further, and found a 3.5-fold decrease in strength of the
scaffolds compared to conventional electrospun silk. Although mechanical strength did
decrease with increased porosity, the decrease for silk was considerably less than the 40fold reduction in tensile strength reported for cryogenically electrospun poly(D,L- lactide)
when compared to conventional electrospun poly(D,L-lactide)
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. Cellular infiltration

appears to be comparable between the cryogenic electrospun silk and poly(D,L-lactide).
In this work, we have demonstrated the potential of cryogenic electrospinning as an
improvement over conventional electrospinning for true three-dimensional cell culture on a
natural polymer. To our knowledge, we report the first electrospun silk scaffold with
enhanced cell infiltration and cell viability as a result of increased void volume throughout
the scaffolds, which has been a limitation of previous studies 65 . We have successfully
demonstrated epithelial cell viability in co-culture with fibroblasts, as well as terminal
differentiation of keratinocyte cultures, and suggest that this new scaffold system can,
potentially, be used for many applications ranging from in vitro three-dimensional cell
culture for tissue modeling as well as in vivo applications for tissue regeneration and
reconstruction.
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Chapter 5: Comparison of Cryogenic Electrospun and In Vivo
Models

INTRODUCTION

HNSCC accounts for 7% of all new cancer occurrences, and has a high morbidity and
recurrence rate in spite of currently available treatments!&*( . It is therefore important to study
tumorigenic mechanisms of this type of cancer further, in order to gain a better understanding
of tumor development and progression. Current in vitro models either fail to be representative
of the three-dimensional environment that supports tumor development in vivo or have not
been rigorously validated to be representative of human disease!& . It is therefore imperative to
develop and validate such a model.
In our previous work, we have shown that cryogenic electrospun silk can be used for
supporting 3D culture of HNSCC cells in co-culture with immortalized fibroblasts!&(& . We
therefore hypothesized that co-culture of HNSCC derived cell lines with a supporting
fibroblast cell line on cryogenic electrospun silk scaffold could be a representative in vitro
model. HN12 cells were derived from metastatic HNSCC in a lymph node, and these cells
have been shown to be tumorigenic in a mouse model!(" . In these studies, we used a coculture of HN12 and BJ-hTERT cells on cryogenic electrospun silk scaffolds as our 3D model
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of HNSCC. Initial validation of this model was accomplished by comparison with tumor
samples from HN12 cells grown in immunodeficient mice. Since HN12 cells are tumorigenic
in a murine model, and interact in 3D with the host microenvironment, comparison of the in
vitro model to this in vivo model is likely to be a good way of validating the in vitro model.
Using HN12 cells in both in vitro and in vivo conditions controls for possible variation
between different HNSCC cell lines.

RESULTS
!

In order to compare the extracellular matrix of the HN12 tumors with the 3D model,
we decellularized a portion of a solid tumor developed by implanting HN12 cells
subcutaneously in nude mice. The decellularized tumor sections were then frozen, freezedried, and examined using a scanning electron microscope. The resulting micrographs are
shown in Figure 5.1, along with micrographs of cryogenic electrospun scaffolds. The average
fiber widths were determined to be 2.24±0.67µm and 2.58±0.75µm for tumor ECM and
cryogenic electrospun silk scaffolds, respectively (no significant difference, with p= 0.075).
Once the scaffold morphology was determined to be representative of the tumor ECM
in terms of fiber width and cell infiltration potential, biological functions of the tumor model
could be evaluated. HN12 cells were grown in the standard monolayer 2D culture system, and
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in the 3D in vitro model, and these were compared to HN12 tumors grown in nude mice.
Gene expression of Ki67, keratin, vimentin, involucrin, and the epidermal growth factor
receptor (EGFR) were evaluated in each model system. Figure 5.2 shows the expression of a
proliferation marker, Ki67, in all respective models and the quantification of the average
fraction of the cells proliferating to the average number of cells present in each model. Due to
the appreciable differences in proliferation and the observation that very few of the cells
present in the tumor appear to be actively dividing; we immunostained for the presence of
involucrin, an early terminal differentiation marker for keratinocytes. Figure 5.3 shows the
involucrin immunoreactivity in each of the tumor models. The HN12 in vivo tumor samples
showed variable expression of involucrin, suggesting non-homogeneous epithelial
differentiation throughout the solid tumor. To verify the epithelial origin of the tumor cells
further, we performed pan-keratin immunofluorescent staining, the results of which are shown
in Figure 5.4.
Keratin was expressed in the large majority of the cells in all models,
indicating the epithelial origin of the HN12 cells. The HN12 nude mouse tumor showed
regions with more intense keratin immunoreactivity than others. However, all regions
examined showed positive keratin expression at varying levels, with a low number of cells not
expressing any keratin, which is consistent with a solid tumor of epithelial origin. A similar
relationship was observed in all in vitro models, consistent with all HN12 cells expressing
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keratin at variable degrees, while no keratin expression was detectable in BJ-hTERT cells,
consistent with their mesenchymal origin.
Based on previous work in our laboratory, HN12 cells appear to have undergone
epithelial to mesenchymal transition (EMT) during tumorigenesis, resulting in a more
invasive phenotype than cells derived from the primary tumor. Thus, immunofluorescence
staining for vimentin was performed to discern whether the mesenchymal phenotype was
maintained in in vivo and in vitro tumor models. Figure 5.5 shows vimentin immunereactivity
in the HNSCC models. Vimentin is expressed in all models, which is consistent with HN12
cells undergoing EMT.
The epidermal growth factor receptor (EGFR) pathway plays a central role in
epithelial homeostasis as well as in many carcinomas, including HNSCC. Therefore, the
expression of EGFR in the HNSCC models is of interest for further studies into tumor
development, or as a potential target for chemotherapy, since EGFR is expressed in many
HNSCC and is often overexpressed in HNSCC metastasis! (T! ' . Figure 5.6 shows the
expression of EGFR in the different HNSCC models. The majority of the tumor cells in the
mouse model expressed EGFR, whereas cells cultured in monolayer expressed the EGFR
albeit at low levels. The 3D co-culture revealed minimal EGFR expression, while HN12 cells
in monoculture in 3D did express low levels of the receptor compared to the negative controls
(Figure B-3).
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Figure 5. 1 SEM of HN12 tumor ECM and cryogenic electrospun silk scaffolds. HN12 tumors harvested from nude
mice were decellularized and freeze-dried for SEM analysis.
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Figure 5. 4 Immunofluorescent staining of tumor models for pan keratin expression. @A&/!>433D!P4:4!#?a4>94I!
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Figure 5. 5 Immunofluorescent staining of tumor models for vimentin expression. @A&/!>433D!P4:4!
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DISCUSSION
The demand for in vitro models that are representative of the endogenous complexity
of human tissues and disease is increasing due to limitations of available systems. Although
human tumor xenograft models are the most commonly used in vivo models of human cancer,
including HNSCC, there are concerns about incompatibilities between certain rodent and
human cytokines as well as the lack of a competent immune system! &' .

The ECM

components, mechanical stimulation, soluble signals, and cell-cell junction complexes all play
important roles in tissue development as well as tumorigenesis!"+ . In this study we compared
the standard monolayer cell culture model and our in vitro 3D model system to the standard in
vivo human tumor xenograft model. We used tumors developed from HN12 cells grown in
immunodeficient mice and compared them to either the conventional 2D model or our 3D
model. The advantage of using the xenograft model was the ability to compare directly the
effects the different microenvironments would have on the same human cancer cells,
controlling for variability between cancer cell lines.
There have been many studies indicating that the ECM stiffness plays a significant
role in cellular response!&'T!", . Many studies have shown that during tumor progression and
transition to a malignant phenotype, the ECM of the tumors is markedly remodeled with
increased stiffness of the matrix! &'T! (+T! ""M"' . The stiffness of the matrix in squamous cell
carcinoma is accompanied by an increase in fiber size!"" . Although there are numerous reports
on the composition of oral SCC ECM! "*M"" , no known studies have reported on the
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morphology of the ECM in terms of fiber dimension and orientation. In order to model the
SCC ECM morphology adequately, we performed SEM analysis of decellularized xenografts.
The ECM produced by the HN12 tumor in vivo appears to be amorphous, with randomly
oriented fibers on the order of two microns thick. Our cryogenic electrospun silk scaffolds
also have randomly oriented fibers with no significant difference in width as shown in Figure
5.1, leading to the conclusion that the scaffolds may adequately mimic the ECM in terms of
morphological features. We then proceeded to evaluate the biological response of cells grown
in the in vitro 3D model compared to in vivo. In order to minimize possible variation from the
choice of cell line, all models were derived from the HN12 cells. Only a small number of the
cells found in the tumor were found to be proliferative. There was consistency between Ki67
expression in the 3D co-culture model of HN12 cells with BJ-hTERT fibroblasts and the in
vivo model, indicating some similarity between the two. In contrast, the 2D model was
significantly different in terms of proliferation markers, with 100% of the HN12 cells
expressing Ki67. The Ki67 expression in 3D monoculture of HN12 cells, was markedly lower
than in 2D, but was still significantly higher than the co-culture with fibroblasts. Involucrin
expression was notable in tumor samples, yet undetectable in 2D culture and barely detectable
in 3D culture of HN12 cells, compared to the negative controls. This indicates that some
tumor cells were able to progress to early terminal differentiation in 3D culture and in vivo,
but the same cells are unable to differentiate at all in 2D culture. Keratin expression and
vimentin expression was abundant throughout the tumor samples and throughout all in vitro
models. Immunoreactivity with anti-human pan keratin and involucrin antibodies in the tumor
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samples indicated that the overwhelming majority of the tumors are composed of HN12 cells,
with a minimal amount of mouse cells infiltrating the tumors, at least for blood vessel
formation. The size of the tumors at >1cm3 is well past the critical tumor volume of 1-3mm3
reported to require a blood supply!&(- , suggesting that the tumors are vascularized as necrotic
areas were not observed and proliferating cells were evenly distributed throughout the tumor
volume. These results indicate that, since the majority of the cells in the tumors were HN12derived, the proliferation rate largely reflects the proliferation of HN12 cells in vivo. The
same observation can be made for the HN12 cells grown in 3D with or without the fibroblasts,
with the proliferation rate reflecting largely the proliferation rate of the HN12 cells in the coculture model. The fibroblasts are predicted to be quiescent, due to their high viability and
low Ki67 expression after up to 3 weeks of culture or co-culture in cryogenic electrospun
scaffolds. The high expression of keratin in co-culture with HN12 cells indicates higher
proportions of HN12 cells than BJ-hTERT cells, which do not express keratins. The ability of
the HN12 cells to express involucrin in vivo or in the 3D culture systems, but not in 2D,
indicated the potential of some HN12 cells to differentiate, while others remain proliferative.
High expression of both keratin and vimentin indicates than HN12 cells still retain their
mesenchymal phenotype subsequent to EMT. The lack of notable expression of EGFR in the
3D models, and minimal expression in 2D, indicates that additional factors may regulate
EGFR expression, since EGFR expression was relatively abundant in vivo.
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Chapter 6: Anticancer Drug Activity in 3D Culture Model

INTRODUCTION

Tumor development and progression has been studied primarily using models in which
cancer cells are grown in monolayer culture on plastic substrata. This simplified system
lacks the sophisticated three-dimensional tissue architecture normally present in human
cancer. Therefore, many elaborate interactions between cancer cells and their
microenvironment are missing in the monolayer system. The shortcomings of this
experimental system have been documented in many studies in terms of variability in DNA
methylation patterns, gene expression, and drug sensitivity between 2D, monolayer culture
systems and 3D extracellular matrix systems!*' . Tumor cells grown in 3D models such as
spheroids or microspheres have been shown to acquire resistance to common
chemotherapeutic drugs such as paclitaxel, doxorubicin and cisplatin, among others!"+T!)'T!)) .
Due to the widespread clinical usage of Taxol to treat various types of cancers, including
HNSCC!). , Taxol was chosen as a representative agent to investigate the drug sensitivity
of HN12 cells in monolayer culture compared to 3D culture.
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RESULTS

The initial experiments were conducted using monolayer culture of HN12 cells to
determine the IC90 concentration of Taxol applied to this cell line in 2D culture. The crystal
violet viability assay revealed that 40nM Taxol applied for 72 hours was sufficient to kill
90% of HN12 cells in 2D culture (Fig 6.1). Further experiments were performed using
40nM Taxol to compare the drug sensitivity of HN12 cells grown in 2D and in 3D on a
cryogenic electrospun silk scaffold. Figure 6.2 shows the results of live/dead analysis and
indicates a dramatic difference of Taxol efficacy between HN12 cells grown in 2D and
HN12 cells grown in 3D, with the latter conditions resulting in minimal sensitivity to
Taxol. We further quantified the effects of Taxol on HN12 cells by determining the
percentage of cells that remain attached after drug treatment compared to the
corresponding DMSO-treated controls, as shown in Figure 6.3. These results show that
although HN12 cells are extremely sensitive to Taxol at 40nM concentration when grown
in 2D, the same cells grown in 3D on electrospun silk scaffolds were relatively resistant to
the same concentration of Taxol. We then performed further studies to determine if higher
concentrations of Taxol would have any effect on HN12 cells grown on 3D electrospun
matrices. Figure 6.4 shows the percentage of attached HN12 cells after 72-hour treatment
with increasing Taxol concentrations well above typical lethal doses used for HN12 or
other carcinoma cell lines!.& . Increased concentrations of Taxol had no significant effect on
the relative numbers of HN12 cells remaining attached to the scaffolds after 72-hour drug
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treatments as compared to the control group with DMSO alone. In order to determine
whether there was a difference in proliferation between treated and untreated HN12 cells
on scaffolds, we immunostained the samples for Ki67 after a 72-hour Taxol treatment.
Figure 6.5 shows the results of Ki67 staining for treated and untreated samples, which
were then fixed for immunofluorescence staining. Consistent with HN12 cell survival, the
numbers of proliferating cells were not significantly affected by Taxol treatment even at
concentrations 25X higher than the IC90 concentration for the same cells grown in 2D (Fig.
6.5).
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Figure 6.1 HN12 cells are sensitive to Taxol in 2D culture. HN12 cells were grown in 2D culture, then
incubated with the indicated doses of Taxol for 72 hours. A crystal violet viability assay was performed to
construct the dose response curve and 40nM Taxol was determined to be the IC90 (n=3, +/- s.e.m.).
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Figure 6.3 HN12 cell survival after 72-hour treatment with 40nM Taxol. HN12 cells were grown in 2D
monolayer culture or on cryogenic electrospun silk scaffolds. Samples were treated with 40nM Taxol or DMSO as
control for 72 hours. Survival was determined by taking the average number of surviving cells from the drug
treated samples and dividing by the corresponding DMSO-treated controls (n=10, +/- s.e.m., p<0.0001).
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Figure 6.4 3D cultured HN12 cells are Taxol resistant. HN12 cells were grown on cryogenic electrospun silk
scaffolds. Samples were treated with the indicated concentrations of Taxol or DMSO as control for 72 hours.
Survival was determined by taking the average number of surviving cells from the drug treated samples and
dividing by the corresponding DMSO treated controls (n=10, +/- s.e.m., p>0.06 for all samples compared to the
DMSO control).

!

-*!

!

!

!

_#(+!;8D#9#$4!>433D!NcQ!

J:83#=4:19#8?!
",!
"+!
(,!
(+!
*,!
*+!
&,!
&+!
,!
+!
G[QO!
<76=:79!

"+!

&*,!

*,+!

,++!

&+++!

01%83!N?KQ!

!

F#GH:4!("!*!01%83!9:4194I!@A&/!>433D!:491#?!;:83#=4:19#$4!>1;1>#9<!#?!'^!>H39H:4"!!
HN12 cells were grown on cryogenic electrospun silk scaffolds. Samples were treated with the
indicated concentrations of Taxol or DMSO as control for 72 hours. The average percentage
of Ki67 positive cells relative to the average total number of cells is reported for each
treatment condition (n=10, +/- s.e.m., p>0.06 for all samples compared to the DMSO control).!
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DISCUSSION

A profound difference between HN12 cells grown under 2D and 3D culture
conditions was observed in terms of sensitivity to the chemotherapeutic drug, Taxol. Our
results show that there is a significant protective effect when HN12 cells are cultured in 3D
on an extracellular matrix-mimicking scaffold, compared to conventional monolayer
culture. Although Taxol is a microtubule-stabilizing drug affecting primarily proliferating
cells, the proportion of proliferating cells did not change after Taxol treatment in 3D
culture. These results are congruent with other studies comparing 2D and 3D culture
conditions for many cell and drug types!"+T!)'T!)) . These results are also consistent with many
studies showing a difference in 2D dose response compared to in vivo studies, with notable
drug resistance unaccounted for by 2D cell culture!"-T!). . These findings suggest that our 3D
culture system may be closer to in vivo conditions experienced by the tumor cells than is
possible to mimic in 2D, thus validating further the use of 3D culture conditions for
modeling HNSCC and testing therapeutic efficacy in vitro. The protective effect afforded
by 3D culture could be explained by cell adhesion-mediated drug resistance (CAM-DR).
CAM-DR has been shown to play a part in doxorubicin and melphalan resistance in human
myeloma cell lines. Myeloma cells pre-exposed to fibronectin were able to upregulate the
!4"1 and !5"1 integrins, which was correlated with drug resistance. Low expression of these
integrins in the same cells also resulted in drug sensitivity with initial exposure to
doxorubicin or melphalan!)-T!.+ . Changes in the composition of the ECM, predominantly
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changes in collagens, fibronectin, tenascin and laminins, have been implicated in SCC
progression in vivo! & . Changes in ECM composition also lead to changes in integrin
binding. Thus, further experiments should focus on integrin binding to the ECM or ECMmimicking scaffolds to determine the mechanisms of the protective effect the scaffolds and
the ECM have for tumor cells when exposed to various chemotherapeutic drugs in vitro
and in vivo respectively. In this work we have demonstrated that cryogenic electrospun silk
scaffolds can be used as a substrate for modeling drug resistance in HN12 cells, and as a
model system for resistance mechanism studies or drug development studies.
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Chapter 7: Angiogenic Factors in the 3D HNSCC Model

INTRODUCTION

The switch to an angiogenic phenotype is critical for tumor progression. HN12 cells
have been shown to be capable of angiogenesis when implanted in immunodeficient mice
and have been shown to secrete factors that promote angiogenesis. Therefore, we
investigated the angiogenic potential of HN12 cells grown in our 3D electrospun scaffold
model. This was accomplished in multiple ways. Telomerase-immortalized human
microvasculature endothelial (TIME) cells were used in the 3D model in co-culture with
the BJ-hTERT and HN12 cells in order to evaluate their response to the 3D model. TIME
cells are reported to form capillary like tubules in Matrigel®!&"+ . Therefore, the ability of
our 3D model to induce similar tubule formation is, potentially, a relevant measure of
angiogenic potential of the model. We also measured angiogenesis promoting factors such
as CXCL5 and VEGF-A! &++T! &**T! &"& . HN12 cells express elevated levels of CXCL5
compared to HN4 cells derived from a synchronous primary tongue tumor in the same
patient and which are not tumorigenic in mice. HN12 cells are tumorigenic; however,
down-regulation of CXCL5 in these cells results in reduced proliferation and invasive
potential and loss of tumorigenicity!&+, . VEGF-A induces angiogenesis by primarily acting
on microvascular endothelial cells, stimulating their proliferation!&**T!&"& .
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RESULTS

TIME cell tubule formation, indicating angiogenic potential, was evaluated by coculture of TIME cells with the 3D in vitro tumor culture system. After a week of co-culture
with the TIME cells, the scaffolds were incubated with FITC-Ac-LDL to label endothelial
cells for microscopy. As shown in Figure 7.1, TIME cells were dispersed throughout the
scaffold, with no discernable tubules apparent in any of the sections.
Cryogenic scaffolds were seeded with HN12 cells, BJ-hTERT fibroblasts, or HN12
cells together with BJ-hTERT fibroblasts, with and without TIME cells. The co-cultures
were propagated for a week, prior to replacing the growth medium with fresh CXCL5-free
and VEGF-A-free media formulations. ELISA analysis was then performed on the
supernatants to measure CXCL5 and VEGF-A production.
There is expression of CXCL5 by HN12 cells grown in 3D scaffolds. There
appears to be an inhibitory effect on CXCL5 expression by the presence of TIME cells,
which do not secrete any CXCL5. There is a statistically significant difference between
CXCL5 release by HN12 cells grown with and without TIME cells. There is also a
significant difference between HN12 cells in co-culture with BJ-hTERT fibroblasts with
and without TIME cells. In order to assess the inhibition of CXCL5 in HN12 cells by
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TIME cells more quantitatively, we grew HN12 cells in 2D culture with or without TIME
cell-conditioned EBM-2. We also grew HN12 cell lines with reduced CXCL5 and CXCR2
expression, and conducted similar TIME-conditioned medium experiments as above. The
results, shown in Figure 7.3, indicate that CXCL5 expression is lower in the samples that
were cultured with TIME cell-conditioned medium compared to the control medium.
Similar results were seen in terms of VEGF-A expression. Figure 7.4 illustrates the
expression of VEGF-A in 3D culture. A similar trend was observed in the reduction of
VEGF-A expression as seen for CXCL5 expression, although not statistically significant
for VEGF-A expression. HN12 cells appear to be the only cells that produce VEGF-A;
therefore, the reduction in VEGF-A expression can only be attributed to interaction with
either TIME cells or BJ-hTERT fibroblasts. Following these results we performed
conditioned medium experiments for HN12 cell grown in 2D with and without TIMEconditioned medium. The HN12 cells with reduced CXCL5 and CXCR2 expression by
shRNA were also used for similar TIME-conditioned medium experiments as above.
VEGF-A expression is shown in Figure 7.5. There was a significant decrease of VEGF-A
expression between the control medium and conditioned medium samples. Based on data
from our laboratory (H. Miyazaki & W.A. Yeudall, unpublished observations), it was
predicted that the overall levels of VEGF-A expression would also be lower in HN12 cells
with reduced CXCL5 expression than in the non-targeting controls (NTC) or the parental
HN12 cell lines. The level of change between control and conditioned medium samples for
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HN12 cells with reduced CXCR2 expression was not as pronounced, although there was
still a significant decrease in VEGF-A expression. These results strongly implicate an
inhibitory role for a soluble factor likely released by TIME cells that blocks CXCL5
production by tumor cells. In TIME conditioned medium there did not appear to be much
of a difference in proliferation between the parental HN12 cells and their reduced CXCL5
or CXCR2 expression counterparts.
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co-cultured with TIME cells for a week. TIME cells were labeled with FITC-Ac-LDL and
cryosectioned for microscopy.
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Figure 7. 2 HN12 cells express CXCL5 in 3D culture. HN12 and BJ-hTERT cells were cultured with or
without TIME cells for a week in EBM-2 without VEGF. One-way ANOVA was performed, indicating that
significant differences were observed between the co-culture groups. Further multiple comparison analysis via
Tukey-HSD test, indicates that all groups are significantly different from each other, except HN12+BJ-hTERT
and HN12+TIME, BJ-hTERT+TIME and BJ-hTERT, and finally HN12+BJ-hTERT+TIME and BJhTERT+TIME (n=6, +/- s.e.m., p<0.01, Appendix D)
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Figure 7. 3 TIME-conditioned EBM-2 inhibits CXCL5 expression (n=6, +/- s.e.m.).
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Figure 7. 4 HN12 cells express VEGF-A in 3D culture. HN12 and BJ-hTERT cells were cultured with or
without TIME cells for a week in EBM-2 without VEGF. One-way ANOVA was performed, indicating that
significant differences were observed between the co-culture groups. Further multiple comparison analysis via
Tukey-HSD test, indicates that all groups are significantly different from each other, except HN12+BJhTERT+TIME and HN12+BJ-hTERT, and HN12+TIME and HN12 (n=6, +/-s.e.m., p<0.01, Appendix D)
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Figure 7. 5 TIME-conditioned EBM-2 inhibits VEGF-A expression (n=6, +/- s.e.m.).
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DISCUSSION

In this chapter we have outlined that, although the 3D cryogenic electrospun silk
model developed for in vitro HNSCC modeling is not sufficient to induce tubule formation
in the scaffolds cultured with TIME cells, the production of angiogenic factors was
significant. HN12 cells grown in the 3D culture system produced much higher levels of
CXCL5 and VEGF-A than the fibroblast controls. It is important to recognize that,
although this in vitro model attempts to mimic the extracellular matrix, it is still a
simplification of in vivo conditions with extremely complex biological functions. We
showed that cell-cell interactions such as the introduction of endothelial cells, can alter
expression of angiogenic factors, with possible negative feedback inhibition. Additionally,
there appears to be a correlation between reduced proliferation and reduced CXCL5 and
VEGF release. HN12 cells grown in co-culture with BJ-hTERT cells have lower
proliferation rates as noted in Chapter 5 with lower Ki67 levels and release lower levels of
CXCL5 and VEGF than HN12 cells on scaffolds alone. The results of subsequent
experiments carried out in 2D culture support the hypothesis that TIME cells inhibit
angiogenic factor release by HN12 cells. The TIME cell-conditioned medium contains all
factors that may be released by TIME cells into the medium. The presence of these factors
appears to have altered the release of both CXCL5 and VEGF-A in HN12 cells, whether
grown under 3D or 2D culture conditions. The 3D model was crucial in enabling us to
make this observation, while 2D culture was a useful tool for confirming the observation
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with more quantitative measures. Future studies into the mechanism of inhibition of
CXCL5 and VEGF release by identifying and isolating, which factors are present in
conditioned medium and which factors contribute to the inhibition process, may lead to the
identification of either a possible inhibitor of angiogenesis in SCC, or a possible target for
chemotherapy for control of angiogenesis.
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Chapter 8: Discussion

Tissue engineered scaffolds have been used primarily for therapeutic in vivo
applications. The premise for developing such scaffolds, whether the scaffolds are directly
implanted or initially pre-seeded with cells, is to develop a niche that will promote cellular
infiltration and remodeling of the scaffold once implanted in the body. This approach takes
into account that the scaffold may not be absolutely identical to the native tissue, however
enough similarities exist that remodeling of the implant leads to regeneration of the tissue.
It has been shown, for example, that scaffolds pre-seeded with human endothelial cells and
either fibroblasts or smooth muscle cells were able to form blood vessels once implanted in
mice!&' . The human endothelial cells comprised the walls of newly formed blood vessels
and were able to carry blood. The sprouting and vessel formation only occurred after
implantation in vivo with the endothelial cells unable to form sprouts in vitro! &' . It is
therefore unclear whether the same approach of building isotropic scaffolds that are
adequate for regenerative applications is satisfactory for 3D in vitro modeling of complex
events that take place during tumor development.
In this work, using a novel scaffold fabrication technique, we were able to
demonstrate that newly developed cryogenic electrospun silk scaffolds were able to
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support epithelial and mesenchymal cell attachment. The cells were able to infiltrate
throughout the volume of the scaffolds. Viability of the cells maintained in our 3D culture
system was high (>95%) throughout the duration of experiments up to 4 weeks of culture.
The cells retained their proliferative capacity as evident by Ki67 staining. Epithelial cells
capable of differentiation in other organotypic models were also able to do so in our 3D
culture system. Therefore our preliminary results indicate cryogenic electrospun silk
scaffolds are able to support mucosal modeling of normal and dysplastic cells.
The primary goal of the described studies was to develop and validate a 3D
HNSCC in vitro model that can be then used for future biologic studies that are impossible
to replicate in two dimensional culture. The minimal requirements for the model were then
determined as developing a scaffold for mimicking the ECM of the tumors, supporting
sufficient nutrient exchange, viability, proliferation, differentiation, drug resistance
potential and angiogenesis potential.

All of these features are observed during

tumorigenesis of human HNSCC, therefore it was important to demonstrate the ability of
the model to encompass as many of these features as possible. Validation to in vivo
conditions was chosen in order to objectively evaluate the strength and weaknesses of the
developed model. The complex biology of tumorigenesis is not completely understood, so
having a model that is close to the in vivo conditions but can be easily manipulated for
studying developmental and proliferative processes, can lead to new information about
how tumor progression can be halted in patients.
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In order to model tumor ECM, one must first know the structure of the native
ECM, in terms of composition but also morphology. The composition of HNSCC tumor
ECM is well known to be primarily composed of collagens, fibronectin, and laminins. The
ECM composition of the HNSCC tumors appears to be closer to the composition of the
normal basement membrane than the stromal components of the dermis. Collagen IV, V,
VII, XI, XVII, fibronectin, and laminins 5, 6, 10/11 are all upregulated and found in the
tumor ECM as opposed to their normal location in the basement membrane! ./ . Other
studies have shown the increase in stiffness of the ECM throughout tumor development
and tumor progression!&(C!.* Increase in ECM stiffness of SCC tumors has been correlated
with an increase in matrix fiber size!.. . Therefore it appears that the morphology of the
tumor ECM is also an important factor in tumorigenesis. Many studies have shown the
significance of fiber dimensions, orientation and resulting matrix stiffness are important
for guiding tissue development processes! &(C! &'( . For these reasons, were performed
decellularization experiments to expose the tumor ECM for SEM analysis. We were able
to observe the random orientation of the ECM fibers and measure their dimension. Then
for 3D tumor modeling, we constructed a scaffold that matches tumor ECM in terms of
fiber dimensions and orientation, based or our SEM analysis of the tumor ECM and the
constructed scaffolds. The chosen biomimetic material, silk fibroin, is known to support
cell adhesion via binding of integrins !2"1, !5"1, !V"1, !V"3!(+M+- . These integrins normally
function in adhesion to collagens I, II, III, IV, laminins and fibronectin!(( many of which
are present in tumor ECM. Therefore the tumor ECM mimicking scaffold that we
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developed, potentially replicates the tumor ECM in morphology (fiber size and orientation)
as well as the availability of potential integrin binding sites.
Our tumor model was then compared in terms of biologic functions to the same
human cell line grown as xenografts in vivo. Many features seen in tumors were also
observed in our models. We demonstrated the ability of the scaffolds to support
heterogeneity in proliferation and differentiation states that was completely absent in 2D
models and was prevalent in vivo. The Ki67, pan keratin, vimentin and involucrin
immunoreactivity experiments show that HN12 cells are able to display heterogeneous
phenotypes when grown in 3D, while mostly homogenous phenotype in 2D culture. All of
the HN12 cells were proliferating in 2D, in contrast to only a fraction of them proliferating
in vivo and in the 3D models. Similar to in vivo tumor cell behavior, the non-proliferating
cells in the 3D model were able to follow different stages of differentiation as indicated by
expression of the early terminal epithelial differentiation marker, involucrin, in only some
of the tumor cells in the 3D model. No indication of differentiation was observed in the 2D
cultures of HN12 cells, which is consistent with a homogenous, proliferating phenotype
(since proliferating cells do not differentiate). The homogenous phenotype is not observed
in vivo, and therefore is not representative of the more complex tumor biology present in
vivo.
Expression of keratin indicates the HN12 cells have not lost their epithelial traits
whether cultured in 2D, or 3D or in vivo. The expression of vimentin indicates that the
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same cells have gained some mesenchymal properties consistent with epithelial to
mesenchymal transition. EMT is often correlated with more invasive phenotypes of
HNSCC, therefore a model system supporting the different stages of disease progression is
highly desirable.
Low immunoreactivity for the EGFR in 3D culture and the lack of endothelial cell
sprouting show that there are limitations to the events that this model can replicate. Many
studies show that silk is an excellent biomaterial for supporting angiogenesis! (.C! (+C! +-M+' ,
therefore there must be other cues present in vivo that are absent in our model for
promotion of angiogenesis. The model was grown under static conditions with no attempt
to mimic blood flow conditions. Such flow conditions are often necessary for a variety of
developmental events, including angiogenesis!&( , therefore it is perhaps not surprising that
angiogenic cues from the tumor cells were insufficient to induce sprouting. This finding is
consistent with previous studies showing endothelial cell sprouting and tubule/capillary
formation in scaffolds only after in vivo implantation!&( .
The standard collagen type I gel model showed little resemblance to the in vivo
events observed in the harvested HN12 tumors. We observed minimal heterogeneity in
HN12 phenotype. HN12 cells did not infiltrate into the gel, with only a single cell layer of
HN12 cells residing on the gel surface, with imbedded fibroblasts throughout the gel. The
HN12 cells were unable to proliferate, with very few cells positive for Ki67 (<1%) and no
indication of differentiation potential (Figure A-1).
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The application of Taxol to the 3D model and comparison with the 2D model
revealed that HN12 cells display variable tolerance for the same drug exposure based on
the microenvironment in which these cells are situated. We were unable to determine the
IC90 for HN12 cells grown in 3D culture since even the highest doses of the drug had no
significant effect on the viability or proliferation of the tumor cells. These findings are
consistent with many other studies arguing for the need for more complex in vitro models
that are more representative of real tissue than the conventional 2D models. Our studies
are also consistent with the in vivo clinical data documenting only a 35-40% response rate
in HNSCC patients treated with Taxol, even though it is one of the highest response rates
reported for any chemotherapeutic drug therapy for HNSCC trials!( . The low response rate
to chemotherapy agents in HNSCC patients is consistent with our in vitro data of no
response to Taxol in 3D culture.
One possible explanation for Taxol not affecting the tumor cells on the scaffold is
that the cell and scaffold density do not allow for Taxol to diffuse into the cells like it does
in 2D culture where most of the cells are exposed to the drug. This explanation would be
plausible if the surface cells on the scaffolds were affected by Taxol, while the deeper
layers of cells were not effected. Through our microscopy analysis, we determined that the
surface cells on the scaffolds were not affected by the drug, just like the cells that
infiltrated deeper in the scaffold volume. Taxol is a relatively small molecule that is able to
diffuse through the cell membrane, where it then attaches to the microtubules!)-C!)& . It is
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unlikely that the scaffold that allows for cells >10µm in diameter to freely infiltrate
through its pores, would be too dense for a drug small enough to pass through the plasma
membrane.
Cell-matrix interactions, in particular integrin binding and downstream signaling, are
good candidates to mediate the protective effect HN12 cells experience when grown in 3D
culture. As previously mentioned, CAM-DR has been observed for myeloma cells, with
integrin binding and NF-%B activation playing a role in the resistance mechanism!)-T!&"* .
One could use an NF-%B inhibitor to block NF-%B activation and conduct the same dose
response studies to determine whether the NF-%B mediated pathway plays a role in the
resistance mechanism. Tumor cells with reduced expression of NF-%B (shNF-%B ) can also
be used for a similar drug study to determine whether NF-%B plays a role in the drug
resistance mechanism. Another study shows that breast cancer cells can be resistant to
Taxol due to AKT mediated mechanism of cytoprotection, activated by cell binding via
!5"1 and !2"1 integrins! .+ . These are the same integrins that have been shown to be
upregulated in SCC cells!& and able to bind to silk scaffolds!')M'- . The integrin mediated
resistance mechanism hypothesis is consistent with our results, since the surface cells on
the scaffolds would likely attach to the scaffolds via the same integrins as the interior cells,
therefore would receive the same survival cues as the interior cells, resulting in no effect of
the drug on any particular population of HN12 cell throughout the scaffolds. In order to
determine whether these integrins play a role in HN12 cell resistance to Taxol, antibodies
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against the integrins could be used to inhibit the particular integrins and repeat our
experiments with Taxol treatments of 2D and 3D cultures of HN12 cells and measuring
whether cell survival would be effected at different Taxol doses. One could also inhibit
downstream targets of these integrins to determine the later stages of the mechanism of
resistance, and again measure the response to Taxol treatment with potential survival
mechanisms inhibited.
Another way to verify that there is a protective effect from 3D conditions is to
compare the results of drug treatment in our scaffolds to an ex vivo or in vivo analogue to
the scaffold. One way to do so would be to perform tissue culture of the explanted tumors
derived from the animals xenografted with HN12 cells, and treating these tumors with
Taxol, while comparing to tumors samples treated with the vehicle control in the same
tissue culture conditions. Although tissue culture of fragments of tissues has been prevalent
since the establishment of this method in 1907 by Harrison! ) , it has been shown to be
incredibly inefficient with only the cells able to grow out of the tissue specimen remaining
viable, therefore tissue culture has been replaced with 2D cell culture! &- . A better
experiment might be to implant HN12 cells in nude mice. Once tumors develop in these
animals, one can treat half of the animals with Taxol and the other half with the vehicle
control and compare the two groups for tumor growth. These experiments have already
been conducted by other groups with other tumor cells including HNSCC tumors!,) , but
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not exclusively with HN12 cells. If resistance to Taxol is observed, the results will be
supportive of our in vitro findings and clinical data for low response rate to Taxol.
Future directions include improving the 3D model as well as applying the
developed model to studying mechanisms of carcinogenesis, drug resistance and possibly
more efficient chemotherapies. Although there are studies indicating that matching the
scaffold fiber size and orientation to native ECM are more important than matching ECM
composition alone! &"( , matching both may be even more effective, using tumor ECM
components such as collagen, fibronectin or laminin. Although silk fibroin does support
integrin adhesion, the RGD amino acid sequences, which are the primary sites for integrin
binding, are missing in the domesticated silk used for these experiments, thus closer
matching the proteins to the native tumor ECM, may close the gaps between in vitro and in
vivo tumor models even further. One notable deficiency of the currently developed model,
was the lack of endothelial cell sprouting and subsequent tubule formation. A way to
improve this aspect of the model is to include flow conditions with a perfusion bioreactor.
Flow conditions mimicking blood flow have been shown to have a substantial effect on
improving cell function in in vitro conditions for tissue modeling!&' , therefore endothelial
cell function may improve with this additional variable.
Another element that is currently completely missing from in vitro modeling of
HNSCC is the contribution of inflammatory cells. Chronic inflammation is well known to
be correlated with cancer development! &"" . Inflammation around tumors contributes to
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tumor proliferation, survival and invasion! &"" . Tumor cells are capable of recruiting a
diverse leukocyte population, including neutrophils, dendritic cells, macrophages,
eosinophils and mast cells by secreting various cytokines and chemokines attracting
leukocytes!&", . These cells produce a barrage of different cell mediators enhancing tumor
survival. One process of particular interest is macrophage-regulated tumor-associated
angiogenesis. Activated macrophages produce TGF-", TNF-! and IL-1! leading to further
release of IL-8 and VEGF-A, thus resulting in promotion of angiogenesis. This is just one
example of a pro-angiogenic pathway induced by inflammatory cells surrounding and
infiltrating the developing tumors!&", . In order to mimic some of these processes in the 3D
model, one could incorporate macrophages in co-culture with the tumor cells, or even
tumor and endothelial cells to see if the pro-angiogenic response will improve, or whether
tubule formation could be observed.
Another future direction is the understanding of the mechanisms of drug resistance,
which may lead to discovery of better chemotherapies or drug delivery systems. Our model
already shows a significant difference between drug sensitivity of HN12 cells in 2D and
3D conditions. It can therefore be used for further evaluation of other drugs and their
efficacy. Using other HNSCC cell lines in the same model instead of HN12 cells would
shed light on whether the conclusions drawn from HN12 experiments are representative of
HNSCC or are limited to this cell line. If the model is then deemed representative, it can be
used for drug discovery purposes. Future experiments could include determining the drug
!

&&'!

!

!

!

resistance mechanism, to then inhibiting this mechanism and using current drugs, or using
completely new drugs, with initial testing in the 3D in vitro model, and then corresponding
animal models, and then clinical trials.

The in vitro experiments for new drug

development could very similar to our methods. The effective dose of the drug could be
determined by applying different doses of the drug and determining the IC90 via viability
or cytotoxicity assays (such as MTT-cytotoxicity assay).
The observation that TIME cells may have an inhibitory effect on HN12 cell
production of angiogenic factors, is an example of possible exploratory avenues that the
3D model offers. If this inhibition is confirmed with follow up experiments with qPCR and
western blot analysis for mRNA and protein, the mechanism of this inhibition could prove
to be important in understanding tumor growth. Determining the factors causing the
inhibition could also lead to development of a potential treatment. The released factors
could be identified by performing mass spectrometry analysis on the TIME-conditioned
medium and fresh medium. Comparing the composition of both media components should
narrow down the possible molecules involved. These can then be selectively applied to 2D
cultures of HN12 cells in a dose responsive manner, while measuring the released levels of
CXCL5 and VEGF-A. Further experiments could be performed by altering the receptors
for the potential inhibitory molecules, or by targeting downstream pathways of the
inhibitory agents.
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The cryogenic electrospun silk 3D model of HNSCC developed and validated in
this work can be used for a variety of studies that require cell-matrix and cell-cell
interactions in vitro that are currently absent in other in vitro models, such as the 2D
monolayer culture of human tumor cell lines. We were able to replicate many features of in
vivo conditions in our 3D model, including similar tumor cell proliferation rates, ability to
support differentiation, viability, cell infiltration throughout the matrix, drug resistance and
production of angiogenic factors. These features are important for tumor development and
growth in vivo and are therefore important to study in vitro, in order to gain a better
understanding of tumor biology and to aid chemotherapeutic drug development and
accurate evaluation of drug efficacy.
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APPENDIX A: Conventional Organotypic 3D Model

Due to the popularity of using the rat tail collagen type I gel model for organotypic
HNSCC modeling! *'M(+ , we replicated the culture conditions for HN12 cells and BJ-hTERT
fibroblasts to evaluate the efficacy of this conventional model compared to the in vivo conditions.
We performed immunofluorescence staining for the Ki67, involucrin, vimentin, EGFR and pan
keratin. The results are shown in Figure A-1. While keratin and vimentin levels were representative
of those seen in vivo, the proliferation of HN12 cells in this model was notably lower than any
other cell culture conditions used as well as much lower than in vivo. The HN12 cells were also not
able to differentiate, as evident from the lack of involucrin immunoreactivity. Another striking
feature observed in this model was the lack of stratification or invasion of HN12 cells into the
matrix. Despite the merits of using this in vitro model for HNSCC, the differences between this
model and native tumor are significant in terms of cell stratification, invasion, proliferation and
lack of signs of differentiation. Depending on the particular experimental parameters, this model
may be advantageous or inadequate. For example, this would be an adequate model to study factors
that may promote HN12 cells to invade into the gel volume.
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APPENDIX B: Negative Controls for Immunofluorescent
Staining

For every immunofluorescent staining experiment, we prepared parallel negative
controls. The following figures show these controls.
All primary antibodies used for our experiments were raised against human
antigens. Therefore, in order to rule out antibody cross-reactivity with mouse antigens,
which may be present in the tumor samples, we performed immunofluorescent staining of
NIH-3T3 cells for Ki67, pan keratin, vimentin, involucrin and EGFR. Figure B-1 shows
the results. These mouse fibroblasts are expected to express Ki67 and vimentin. They are
not expected to express epithelial cell markers, pan keratin, involucrin and EGFR,
therefore no staining for these markers of the 3T3 cells does not indicate that the antibodies
used will not cross react with mouse cells expressing these factors. However, at exposures
normally used for human samples throughout all above experiments, there was no notable
cross-reactivity of the anti-Ki67 and anti-vimentin antibodies used.
All samples for immunofluorescence microscopy were also used as negative
controls for secondary antibody specificity. For these negative control samples, the
primary antibody was completely omitted, and only the secondary FITC conjugated
antibodies were used. The same exposure levels were used for the experimental samples as
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for the negative controls. Figure B-2 shows the negative controls for the HN12 tumor
samples stained with anti-mouse and anti-rabbit FITC-conjugated secondary antibodies.
Figure B-3 shows the negative controls for the 2D HN12 samples stained with antimouse and anti-rabbit FITC-conjugated secondary antibodies. Figure B-4 shows the
negative controls for the 3D HN12+BJ-hTERT co-culture samples stained with anti-mouse
and anti-rabbit FITC-conjugated secondary antibodies. Finally, Figure B-5 shows the
negative controls for the 3D HN12 culture samples stained with anti-mouse and anti-rabbit
FITC-conjugated secondary antibodies. There was no significant non-specific binding of
secondary antibodies observed in any of the negative controls.
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APPENDIX C: Gene Expression Testing in Cryogenic
Electrospun Silk Scaffolds

Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR)
are routine procedures in cell biology to determine whether certain proteins and mRNA are
present. It is often simple to perform this analysis on cells grown in monolayer culture on
tissue culture plastic. Such analysis is often difficult to perform on electrospun scaffolds,
with difficulties of obtaining sufficient protein or mRNA for conclusive analysis.
Therefore we attempted standard protocols for western blotting and qRT-PCR to determine
whether such common techniques could be used to analyze cells grown on cryogenically
electrospun silk scaffolds. We performed a western blot analysis for expression of EPS8 on
HN12 cells seeded on cryogenically electrospun silk scaffolds normalized to the level of
actin these cells express. Figure A-1 demonstrates detection of EPS8 and actin by HN12
cells grown on silk scaffolds, with HN12 cells grown in monolayer culture on tissue
culture plastic as a positive control and cryogenic electrospun silk scaffolds with no cells
as a negative control. QRT-PCR analysis was not possible due to the inefficiency of the
attempts at extracting RNA from electrospun scaffolds.

The RNA extraction using

standard Trizol protocols consistently lead to RNA concentrations well below 1µg/µL
measure by the Nanodrop spectrophotometer. The concentration reading was not
significantly higher than the negative controls, and much lower that the positive controls.
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Optimization steps of adding the freeze/thaw cycle for more efficient cell lysis, or
mechanically disrupting the scaffolds to allow for increased Trizol/cell interaction, had
little to no effect on improving the RNA extraction efficiency.
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APPENDIX D: One-Way Analysis of Variance

We performed a one-way analysis of variance (ANOVA) on the CXCL5 release
data comparing co-cultures of HN12 cell with BJ-hTERT and TIME cells on cryogenic
electrospun silk scaffolds. Table D-1 documents the results of the ANOVA, indicating that
there are statistically significant differences between the co-culture groups in terms of their
CXCL5 release. The Tukey’s honesty significant difference (HSD) test was performed to
determine which groups were statistically significantly different from each other. Table D2 shows the results of the HSD test.
The same ANOVA analysis was performed on the VEGF-A release data comparing
co-cultures of HN12 cell with BJ-hTERT and TIME cells on cryogenic electrospun silk
scaffolds. Table D-3 documents the results of the ANOVA, indicating that there are
statistically significant differences between the co-culture groups in terms of their VEGF
release. The HSD test was performed on these grounds as well. Table D-2 shows the
results of the HSD test.
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Between:
Within:
Total:
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SS

df

MS

F

p

39,980.57
14,578.27
54,558.84

5
30
35

7,996.11
485.942

16.455

<0.0001
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Group
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+TIME
HN12+TIME
HN12+TIME
HN12+TIME
HN12+TIME
HN12+TIME
HN12
HN12
HN12
HN12
HN12
HN12
BJ-hTERT+TIME
BJ-hTERT+TIME
BJ-hTERT+TIME
BJ-hTERT+TIME
BJ-hTERT+TIME
BJ-hTERT+TIME
BJ-hTERT
BJ-hTERT
BJ-hTERT
BJ-hTERT
BJ-hTERT
BJ-hTERT
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Group
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
BJ-hTERT+TIME
BJ-hTERT
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
BJ-hTERT+TIME
BJ-hTERT
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
BJ-hTERT+TIME
BJ-hTERT
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
BJ-hTERT+TIME
BJ-hTERT
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
BJ-hTERT+TIME
BJ-hTERT
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
BJ-hTERT+TIME
BJ-hTERT

Tukey’s HSD Comparison
N/A
28.809
29.028
47.83
0.219
19.027
28.809
N/A
0.219
19.02
32.41
18.8
29.028
0.219
N/A
18.8
32.63
33.81
47.83
19.02
18.8
N/A
51.44
52.62
0.219
32.41
32.63
51.44
N/A
1.18
19.027
18.8
33.81
52.62
1.18
N/A

Significance (p<0.01)
N/A
Significant
Significant
Significant
Not Significant
Significant
Significant
N/A
Not Significant
Significant
Significant
Significant
Significant
Not Significant
N/A
Significant
Significant
Significant
Significant
Significant
Significant
N/A
Significant
Significant
Not Significant
Significant
Significant
Significant
N/A
Not Significant
Significant
Significant
Significant
Significant
Not Significant
N/A
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Between:
Within:
Total:
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SS

df

MS

F

p

101,614.90
48,950.67
150,565.58

3
20
23

33,871.63
2,447.53

13.839

<0.0001
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Group
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+BJ-hTERT
HN12+TIME
HN12+TIME
HN12+TIME
HN12+TIME
HN12
HN12
HN12
HN12
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Group
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12
HN12+BJ-hTERT+TIME
HN12+BJ-hTERT
HN12+TIME
HN12

Tukey’s HSD Comparison
N/A
0.867
4.968
7.992
0.867
N/A
4.101
7.125
4.968
4.101
N/A
3.024
7.992
7.125
3.024
N/A

Significance (p<0.01)
N/A
Not Significant
Significant
Significant
Not Significant
N/A
Significant
Significant
Significant
Significant
N/A
Not Significant
Significant
Significant
Not Significant
N/A
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APPENDIX E: HN12 Tumor Histology

HN12 tumors that were harvested from nude mice, and cryosectioned were also stained
with Hematoxylin and Eosin for histological analysis. Figure E-1 shows a representative
H&E stained section through the HN12 tumors.
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